JPWO2019147831A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019147831A5
JPWO2019147831A5 JP2020540397A JP2020540397A JPWO2019147831A5 JP WO2019147831 A5 JPWO2019147831 A5 JP WO2019147831A5 JP 2020540397 A JP2020540397 A JP 2020540397A JP 2020540397 A JP2020540397 A JP 2020540397A JP WO2019147831 A5 JPWO2019147831 A5 JP WO2019147831A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antigen
seq
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540397A
Other languages
Japanese (ja)
Other versions
JP2021511058A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014978 external-priority patent/WO2019147831A1/en
Publication of JP2021511058A publication Critical patent/JP2021511058A/en
Publication of JPWO2019147831A5 publication Critical patent/JPWO2019147831A5/ja
Priority to JP2023177262A priority Critical patent/JP2024009962A/en
Pending legal-status Critical Current

Links

Claims (30)

（ａ）配列番号２、１７もしくは１９に示されるアミノ酸配列を含む免疫グロブリン重鎖のＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２、およびＣＤＲ－Ｈ３を含む免疫グロブリン重鎖可変領域；ならびに／または
（ｂ）配列番号４もしくは１８に示されるアミノ酸配列を含む免疫グロブリン軽鎖のＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２、およびＣＤＲ－Ｌ３を含む免疫グロブリン軽鎖可変領域
を含む、ヒトＴＭＰＲＳＳ２に特異的に結合するヒト抗原結合タンパク質。 (A) Immunoglobulin heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 of an immunoglobulin heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 2, 17 or 19; and / or the sequence (b). Human antigen binding specifically binding to human TMPRSS2, comprising the immunoglobulin light chain variable region comprising CDR-L1, CDR-L2, and CDR-L3 of the immunoglobulin light chain comprising the amino acid sequence set forth in number 4 or 18. protein. 抗体またはその抗原結合断片である、請求項１に記載の抗原結合タンパク質。 The antigen-binding protein according to claim 1, which is an antibody or an antigen-binding fragment thereof. （ａ）配列番号２、１７もしくは１９に示されるアミノ酸配列と少なくとも９０％のアミノ酸配列同一性を有するアミノ酸配列を含む重鎖免疫グロブリン可変領域；および／または
（ｂ）配列番号４もしくは１８に示されるアミノ酸配列と少なくとも９０％のアミノ酸配列同一性を有するアミノ酸配列を含む軽鎖免疫グロブリン可変領域
を含む、請求項１または２に記載の抗原結合タンパク質。 (A) Heavy chain immunoglobulin variable region comprising an amino acid sequence having at least 90% amino acid sequence identity with the amino acid sequence set forth in SEQ ID NO: 2, 17 or 19; and / or (b) set forth in SEQ ID NO: 4 or 18. The antigen-binding protein according to claim 1 or 2, which comprises a light chain immunoglobulin variable region comprising an amino acid sequence having at least 90% amino acid sequence identity with the amino acid sequence. （ａ）配列番号２、１７もしく１９に示されるアミノ酸配列および配列番号２、１７もしく１９に示されるアミノ酸配列と少なくとも９０％のアミノ酸配列同一性を含む重鎖免疫グロブリンのＣＤＲ－Ｈ１、ＣＤＲ－Ｈ２およびＣＤＲ－Ｈ３を含む免疫グロブリン重鎖可変領域；ならびに／または
（ｂ）配列番号４もしくは１８に示されるアミノ酸配列および配列番号４もしくは１８に示されるアミノ酸配列と少なくとも９０％のアミノ酸配列同一性を含む軽鎖免疫グロブリンのＣＤＲ－Ｌ１、ＣＤＲ－Ｌ２およびＣＤＲ－Ｌ３を含む免疫グロブリン軽鎖可変領域を含む、請求項１～３のいずれか１項に記載の抗原結合タンパク質。 (A) CDR-H1 of a heavy chain immunoglobulin containing at least 90% amino acid sequence identity with the amino acid sequence set forth in SEQ ID NOs: 2, 17 or 19 and the amino acid sequence set forth in SEQ ID NOs: 2, 17 or 19. Immunoglobulin heavy chain variable region containing CDR-H2 and CDR-H3; and / or (b) the amino acid sequence set forth in SEQ ID NO: 4 or 18 and the amino acid sequence set forth in SEQ ID NO: 4 or 18 and at least 90% of the amino acid sequence. The antigen-binding protein according to any one of claims 1 to 3, which comprises an immunoglobulin light chain variable region containing CDR-L1, CDR-L2 and CDR-L3 of a light chain immunoglobulin comprising identity. （ａ）アミノ酸配列：ＱＳＩＳＳＷ（配列番号１２）を含むＣＤＲ－Ｌ１、
（ｂ）アミノ酸配列：ＫＡＳ（配列番号１４）を含むＣＤＲ－Ｌ２、および／もしくは
（ｃ）アミノ酸配列：ＱＱＹＮＳＹＳＹＴ（配列番号１６）を含むＣＤＲ－Ｌ３
を含む軽鎖免疫グロブリン可変領域；ならびに／または
（ａ）アミノ酸配列：ＧＦＴＦＳＳＹＧ（配列番号６）を含むＣＤＲ－Ｈ１、
（ｂ）アミノ酸配列：ＩＷＮＤＧＳＹＶ（配列番号８）を含むＣＤＲ－Ｈ２、
（ｃ）アミノ酸配列：ＡＲＥＧＥＷＶＬＹＹＦＤＹ（配列番号１０）を含むＣＤＲ－Ｈ３を含む重鎖免疫グロブリン可変領域
を含む、請求項１～４のいずれか１項に記載の抗原結合タンパク質。 (A) Amino acid sequence: CDR-L1 containing QSISSW (SEQ ID NO: 12),
(B) Amino acid sequence: CDR-L2 containing KAS (SEQ ID NO: 14) and / or (c) Amino acid sequence: CDR-L3 containing QQYNSYSSYS (SEQ ID NO: 16).
Light chain immunoglobulin variable region comprising; and / or (a) amino acid sequence: CDR-H1, comprising GFTFSSYG (SEQ ID NO: 6),
(B) Amino acid sequence: CDR-H2 containing IWNDGSYV (SEQ ID NO: 8),
(C) The antigen-binding protein according to any one of claims 1 to 4, which comprises a heavy chain immunoglobulin variable region containing CDR-H3 containing an amino acid sequence: AREGWVLYYFDY (SEQ ID NO: 10). （ａ）配列番号１７もしくは１９に示されるアミノ酸配列を含む重鎖免疫グロブリン、もしくは配列番号２に示されるアミノ酸配列を含む免疫グロブリン重鎖可変領域；
および／または
（ｂ）配列番号１８に示されるアミノ酸配列を含む軽鎖免疫グロブリン、もしくは配列番号４に示されるアミノ酸配列を含む免疫グロブリン軽鎖可変領域
を含む、請求項１～５のいずれか１項に記載の抗原結合タンパク質。 (A) Heavy chain immunoglobulin containing the amino acid sequence set forth in SEQ ID NO: 17 or 19, or immunoglobulin heavy chain variable region containing the amino acid sequence set forth in SEQ ID NO: 2.
And / or (b) any one of claims 1-5, comprising a light chain immunoglobulin comprising the amino acid sequence set forth in SEQ ID NO: 18 or an immunoglobulin light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4. The antigen-binding protein according to the section. ＴＭＰＲＳＳ２への結合をめぐって、請求項１～６のいずれか１項に記載の抗原結合タンパク質と競合し、および／またはＴＭＰＲＳＳ２上の同一の、もしくは重複するエピトープに結合する抗原結合タンパク質。 An antigen-binding protein that competes with the antigen-binding protein according to any one of claims 1 to 6 for binding to TMPRSS2 and / or binds to the same or overlapping epitope on TMPRSS2. 多特異的である、請求項１～７のいずれか１項に記載の抗原結合タンパク質。 The antigen-binding protein according to any one of claims 1 to 7, which is multispecific. 以下の特性：
・ＴＭＰＲＳＳ２発現細胞におけるインフルエンザウイルスの増殖を阻害する；
・ＴＭＰＲＳＳ発現細胞の表面に結合する；
・ＴＭＰＲＳＳ２を発現しないＭＤＣＫ／Ｔｅｔ－ｏｎ細胞に有意に結合しない；
・約２５℃で約２．８１×１０-9ＭのＫDでヒトＴＭＰＲＳＳ２に結合する；
・約３７℃で約９．３１×１０-9ＭのＫDでヒトＴＭＰＲＳＳ２に結合する；
・約２５℃で約５．６０×１０-8ＭのＫDでカニクイザルＴＭＰＲＳＳ２に結合する；
・約３７℃で約１．４０×１０-7ＭのＫDでカニクイザルＴＭＰＲＳＳ２に結合する；
・インビトロでの細胞のインフルエンザウイルス感染の拡大を制限する；および／または・ヒトＴＭＰＲＳＳ２タンパク質を発現するように操作されたマウスを、インフルエンザウイルス感染によって引き起こされる死から保護する
のうちの１つまたはそれ以上を含む、請求項１～８のいずれか１項に記載の抗原結合タンパク質。 The following characteristics:
-Inhibits the growth of influenza virus in TMPRSS2-expressing cells;
-Binds to the surface of TMPRSS-expressing cells;
-Does not significantly bind to MDCK / Tet-on cells that do not express TMPRSS2;
-Binds to human TMPRSS2 at about 2.81 x 10 -9 M KD at about 25 ° C;
-Binds to human TMPRSS2 at about 9.31 × 10 -9 M KD at about 37 ° C;
-Binds to cynomolgus monkey TMPRSS2 at about 5.60 x 10 -8 M KD at about 25 ° C;
-Binds to cynomolgus monkey TMPRSS2 at about 1.40 x 10 -7 M KD at about 37 ° C;
-Limiting the spread of influenza virus infection of cells in vitro; and / or-one of the protections for mice engineered to express the human TMPRSS2 protein from death caused by influenza virus infection or it. The antigen-binding protein according to any one of claims 1 to 8, which comprises the above. ＴＭＰＲＳＳ２ポリペプチドに結合した、請求項１～９のいずれか１項に記載の抗原結合タンパク質を含む複合体。 A complex comprising the antigen-binding protein according to any one of claims 1 to 9, which is bound to a TMPRSS2 polypeptide. 請求項１～９のいずれか１項に記載の抗原結合タンパク質またはその免疫グロブリン鎖を作製する方法であって、
（ａ）前記抗原結合タンパク質の免疫グロブリン鎖をコードする１つもしくはそれ以上のポリヌクレオチドを導入する工程；
（ｂ）該ポリヌクレオチドの発現に適した条件下で宿主細胞を培養する工程；
（ｃ）場合により、該宿主細胞、および／または該宿主細胞が増殖される培地から該抗原結合タンパク質もしくは免疫グロブリン鎖を単離する工程
を含む前記方法。 The method for producing an antigen-binding protein according to any one of claims 1 to 9 or an immunoglobulin chain thereof.
(A) A step of introducing one or more polynucleotides encoding the immunoglobulin chain of the antigen-binding protein;
(B) A step of culturing a host cell under conditions suitable for expression of the polynucleotide;
(C) The method comprising, optionally, isolating the antigen-binding protein or immunoglobulin chain from the host cell and / or the medium in which the host cell is grown. 宿主細胞はチャイニーズハムスター卵巣細胞である、請求項１１に記載の方法。 11. The method of claim 11, wherein the host cell is a Chinese hamster ovary cell. 請求項１１または１２に記載の方法の生成物である抗原結合タンパク質または免疫グロブリン鎖。 An antigen-binding protein or immunoglobulin chain that is the product of the method of claim 11 or 12. ポリペプチドであって、
（ａ）配列番号２に示されるアミノ酸配列を含む免疫グロブリン鎖のＶHドメインのＣＤＲ１、ＣＤＲ２、およびＣＤＲ３；または
（ｂ）配列番号４に示されるアミノ酸配列を含む免疫グロブリン鎖のＶLドメインのＣＤＲ１、ＣＤＲ２、およびＣＤＲ３
を含む前記ポリペプチド。 It ’s a polypeptide,
(A) CDR1, CDR2, and CDR3 of the V H domain of the immunoglobulin chain comprising the amino acid sequence set forth in SEQ ID NO: 2; or (b) the VL domain of the immunoglobulin chain comprising the amino acid sequence set forth in SEQ ID NO: 4. CDR1, CDR2, and CDR3
The polypeptide comprising. ポリペプチドであって、
（ａ）配列番号２に示されるアミノ酸配列を含む免疫グロブリン鎖のＶHドメインのＣＤＲ１、ＣＤＲ２、およびＣＤＲ３；または
（ｂ）配列番号１８に示されるアミノ酸配列を含む免疫グロブリン鎖のＶLドメインのＣＤＲ１、ＣＤＲ２、およびＣＤＲ３
を含む前記ポリペプチド。 It ’s a polypeptide,
(A) CDR1, CDR2, and CDR3 of the V H domain of the immunoglobulin chain comprising the amino acid sequence set forth in SEQ ID NO: 2; or (b) the VL domain of the immunoglobulin chain comprising the amino acid sequence set forth in SEQ ID NO: 18. CDR1, CDR2, and CDR3
The polypeptide comprising. 請求項１４または１５に記載のポリペプチドをコードするポリヌクレオチド。 A polynucleotide encoding the polypeptide according to claim 14 or 15. 請求項１６に記載のポリヌクレオチドを含むベクター。 A vector comprising the polynucleotide according to claim 16. 請求項１～９および１３～１７のいずれか１項に記載の抗原結合タンパク質または免疫グロブリン鎖またはポリペプチドまたはポリヌクレオチドまたはベクターを含む宿主細胞。 A host cell comprising the antigen-binding protein or immunoglobulin chain or polypeptide or polynucleotide or vector according to any one of claims 1 to 9 and 13 to 17. さらなる治療剤を伴って、請求項１～９のいずれか１項に記載の抗原結合タンパク質または請求項１４もしくは１５に記載のポリペプチドを含む組成物またはキット。 A composition or kit comprising the antigen-binding protein according to any one of claims 1 to 9 or the polypeptide according to claim 14 or 15, with a further therapeutic agent. 請求項１～９のいずれか１項に記載の抗原結合タンパク質または請求項１４もしくは１５に記載のポリペプチド、ならびに薬学的に許容される担体、および場合によりさらなる治療剤を含む医薬組成物。 A pharmaceutical composition comprising the antigen-binding protein according to any one of claims 1 to 9 or the polypeptide according to claim 14 or 15, a pharmaceutically acceptable carrier, and optionally an additional therapeutic agent. 抗ウイルス薬またはワクチンであるさらなる治療剤が伴う、請求項１９または２０に記載の組成物またはキット。 The composition or kit of claim 19 or 20, comprising an additional therapeutic agent, which is an antiviral agent or vaccine. さらなる治療剤は、レジパシビル、ソホスブビル、レジパシビルとソホスブビルの組合せ、オセルタミビル、ザナミビル、リバビリンおよびインターフェロン－アルファ２ｂ、インターフェロン－アルファ２ａ、抗癌剤、ならびにインフルエンザＨＡに特異的に結合する抗体またはその抗原結合断片からなる群から選択されるメンバー；ならびに／またはＨ１Ｈ１４６１１Ｎ２；Ｈ１Ｈ１４６１２Ｎ２；Ｈ１Ｈ１１７２３Ｐ；Ｈ１Ｈ１１７２９Ｐ；Ｈ１Ｈ１１８２０Ｎ；Ｈ１Ｈ１１８２９Ｎ；Ｈ１Ｈ１１８２９Ｎ２；Ｈ２ａＭ１１８２９Ｎ；Ｈ２Ｍ１１８３０Ｎ；Ｈ１Ｈ１１８３０Ｎ２；Ｈ１Ｈ１１９０３Ｎ；Ｈ１Ｈ１４５７１Ｎ；Ｈ２ａ１４５７１Ｎ；Ｈ１Ｈ１１７０４Ｐ；Ｈ１Ｈ１１７１１Ｐ；Ｈ１Ｈ１１７１４Ｐ；Ｈ１Ｈ１１７１７Ｐ；Ｈ１Ｈ１１７２４Ｐ；Ｈ１Ｈ１１７２７Ｐ；Ｈ１Ｈ１１７３０Ｐ２；Ｈ１Ｈ１１７３１Ｐ２；Ｈ１Ｈ１１７３４Ｐ２；Ｈ１Ｈ１１７３６Ｐ２；Ｈ１Ｈ１１７４２Ｐ２；Ｈ１Ｈ１１７４４Ｐ２；Ｈ１Ｈ１１７４５Ｐ２；Ｈ１Ｈ１１７４７Ｐ２；Ｈ１Ｈ１１７４８Ｐ２；Ｈ１Ｈ１７９５２Ｂ；Ｈ１Ｈ１７９５３Ｂ；Ｈ１Ｈ１７９５４Ｂ；Ｈ１Ｈ１７９５５Ｂ；Ｈ１Ｈ１７９５６Ｂ；Ｈ１Ｈ１７９５７Ｂ；Ｈ１Ｈ１７９５８Ｂ；Ｈ１Ｈ１７９５９Ｂ；Ｈ１Ｈ１７９６０Ｂ；Ｈ１Ｈ１７９６１Ｂ；Ｈ１Ｈ１７９６２Ｂ；Ｈ１Ｈ１７９６３Ｂ；Ｈ１Ｈ１７９６４Ｂ；Ｈ１Ｈ１７９６５Ｂ；Ｈ１Ｈ１７９６６Ｂ；Ｈ１Ｈ１７９６７Ｂ；Ｈ１Ｈ１７９６８Ｂ；Ｈ１Ｈ１７９６９Ｂ；Ｈ１Ｈ１７９７０Ｂ；Ｈ１Ｈ１７９７１Ｂ；Ｈ１Ｈ１７９７２Ｂ；Ｈ１Ｈ１７９７３Ｂ；Ｈ１Ｈ１７９７
４Ｂ；Ｈ１Ｈ１７９７５Ｂ；Ｈ１Ｈ１７９７６Ｂ；Ｈ１Ｈ１７９７７Ｂ；Ｈ１Ｈ１７９７８Ｂ；Ｈ１Ｈ１７９７９Ｂ；Ｈ１Ｈ１７９８０Ｂ；Ｈ１Ｈ１７９８１Ｂ；Ｈ１Ｈ１７９８２Ｂ；Ｈ１Ｈ１７９８３Ｂ；Ｈ１Ｈ１７９８４Ｂ；Ｈ１Ｈ１７９８５Ｂ；Ｈ１Ｈ１７９８６Ｂ；Ｈ１Ｈ１７９８７Ｂ；Ｈ１Ｈ１７９８８Ｂ；Ｈ１Ｈ１７９８９Ｂ；Ｈ１Ｈ１７９９０Ｂ；Ｈ１Ｈ１７９９１Ｂ；Ｈ１Ｈ１７９９２Ｂ；Ｈ１Ｈ１７９９３Ｂ；Ｈ１Ｈ１７９９４Ｂ；Ｈ１Ｈ１７９９５Ｂ；Ｈ１Ｈ１７９９６Ｂ；Ｈ１Ｈ１７９９７Ｂ；Ｈ１Ｈ１７９９８Ｂ；Ｈ１Ｈ１７９９９Ｂ；Ｈ１Ｈ１８０００Ｂ；Ｈ１Ｈ１８００１Ｂ；Ｈ１Ｈ１８００２Ｂ；Ｈ１Ｈ１８００３Ｂ；Ｈ１Ｈ１８００４Ｂ；Ｈ１Ｈ１８００５Ｂ；Ｈ１Ｈ１８００６Ｂ；Ｈ１Ｈ１８００７Ｂ；Ｈ１Ｈ１８００８Ｂ；Ｈ１Ｈ１８００９Ｂ；Ｈ１Ｈ１８０１０Ｂ；Ｈ１Ｈ１８０１１Ｂ；Ｈ１Ｈ１８０１２Ｂ；Ｈ１Ｈ１８０１３Ｂ；Ｈ１Ｈ１８０１４Ｂ；Ｈ１Ｈ１８０１５Ｂ；Ｈ１Ｈ１８０１６Ｂ；Ｈ１Ｈ１８０１７Ｂ；Ｈ１Ｈ１８０１８Ｂ；Ｈ１Ｈ１８０１９Ｂ；Ｈ１Ｈ１８０２０Ｂ；Ｈ１Ｈ１８０２１Ｂ；Ｈ１Ｈ１８０２２Ｂ；Ｈ１Ｈ１８０２３Ｂ；Ｈ１Ｈ１８０２４Ｂ；Ｈ１Ｈ１８０２５Ｂ；Ｈ１Ｈ１８０２６Ｂ；Ｈ１Ｈ１８０２７Ｂ；Ｈ１Ｈ１８０２８Ｂ；Ｈ１Ｈ１８０２９Ｂ；Ｈ１Ｈ１８０３０Ｂ；Ｈ１Ｈ１８０３１Ｂ；Ｈ１Ｈ１８０３２Ｂ；Ｈ１Ｈ１８０３３Ｂ；Ｈ１Ｈ１８０３４Ｂ；Ｈ１Ｈ１８０３５Ｂ；Ｈ１Ｈ１８０３７Ｂ；Ｈ１Ｈ１８０３８Ｂ；Ｈ１Ｈ１８０３９Ｂ；Ｈ１Ｈ１８０４０Ｂ；Ｈ１Ｈ１８０４１Ｂ；Ｈ１Ｈ１８０４２Ｂ；Ｈ１Ｈ１８０４３Ｂ；Ｈ１Ｈ１８０４４Ｂ；Ｈ１Ｈ１８０４５Ｂ；Ｈ１Ｈ１８０４６Ｂ；Ｈ１Ｈ１８０４７Ｂ；Ｈ１Ｈ１８０４８Ｂ；Ｈ１Ｈ１８０４９Ｂ；Ｈ１Ｈ１８０５１Ｂ；Ｈ１Ｈ１８０５２Ｂ；Ｈ１Ｈ１８０５３Ｂ；Ｈ１Ｈ１８０５４Ｂ；Ｈ１Ｈ１８０５５Ｂ；Ｈ１Ｈ１８０５６Ｂ；Ｈ１Ｈ１８０５７Ｂ；Ｈ１Ｈ１８０５８Ｂ；Ｈ１Ｈ１８０５９Ｂ；Ｈ１Ｈ１８０６０Ｂ；Ｈ１Ｈ１８０６１Ｂ；Ｈ１Ｈ１８０６２Ｂ；Ｈ１Ｈ１８０６３Ｂ；Ｈ１Ｈ１８０６４Ｂ；Ｈ１Ｈ１８０６５Ｂ；Ｈ１Ｈ１８０６６Ｂ；Ｈ１Ｈ１８０６７Ｂ；Ｈ１Ｈ１８０６８Ｂ；Ｈ１Ｈ１８０６９Ｂ；Ｈ１Ｈ１８０７０Ｂ；Ｈ１Ｈ１８０７１Ｂ；Ｈ１Ｈ１８０７２Ｂ；Ｈ１Ｈ１８０７３Ｂ；Ｈ１Ｈ１８０７４Ｂ；Ｈ１Ｈ１８０７５Ｂ；Ｈ１Ｈ１８０７６Ｂ；Ｈ１Ｈ１８０７７Ｂ；Ｈ１Ｈ１８０７８Ｂ；Ｈ１Ｈ１８０７９Ｂ；Ｈ１Ｈ１８０８０Ｂ；Ｈ１Ｈ１８０８１Ｂ；Ｈ１Ｈ１８０８２Ｂ；Ｈ１Ｈ１８０８３Ｂ；Ｈ１Ｈ１８０８４Ｂ；Ｈ１Ｈ１８０８５Ｂ；Ｈ１Ｈ１８０８６Ｂ；Ｈ１Ｈ１８０８７Ｂ；Ｈ１Ｈ１８０８８Ｂ；Ｈ１Ｈ１８０８９Ｂ；Ｈ１Ｈ１８０９０Ｂ；Ｈ１Ｈ１８０９１Ｂ；Ｈ１Ｈ１８０９２Ｂ；Ｈ１Ｈ１８０９３Ｂ；Ｈ１Ｈ１８０９４Ｂ；Ｈ１Ｈ１８０９５Ｂ；Ｈ１Ｈ１８０９６Ｂ；Ｈ１Ｈ１８０９７Ｂ；Ｈ１Ｈ１８０９８Ｂ；Ｈ１Ｈ１８０９９Ｂ；Ｈ１Ｈ１８１００Ｂ；Ｈ１Ｈ１８１０１Ｂ；Ｈ１Ｈ１８１０２Ｂ；Ｈ１Ｈ１８１０３Ｂ；Ｈ１Ｈ１８１０４Ｂ；Ｈ１Ｈ１８１０５Ｂ；Ｈ１Ｈ１８１０７Ｂ；Ｈ１Ｈ１８１０８Ｂ；Ｈ１Ｈ１８１０９Ｂ；Ｈ１Ｈ１８１１０Ｂ；Ｈ１Ｈ１８１１１Ｂ；Ｈ１Ｈ１８１１２Ｂ；Ｈ１Ｈ１８１１３Ｂ；Ｈ１Ｈ１８１１４Ｂ；Ｈ１Ｈ１８１１５Ｂ；Ｈ１Ｈ１８１１６Ｂ；Ｈ１Ｈ１８１１７Ｂ；Ｈ１Ｈ１８１１８Ｂ；Ｈ１Ｈ１８１１９Ｂ；Ｈ１Ｈ１８１２０Ｂ；Ｈ１Ｈ１８１２１Ｂ；Ｈ１Ｈ１８１２２Ｂ；Ｈ１Ｈ１８１２３Ｂ；Ｈ１Ｈ１８１２４Ｂ；Ｈ１Ｈ１８１２５Ｂ；Ｈ１Ｈ１８１２６Ｂ；Ｈ１Ｈ１８１２７Ｂ；Ｈ１Ｈ１８１２８Ｂ；Ｈ１Ｈ１８１２９Ｂ；Ｈ１Ｈ１８１３０Ｂ；Ｈ１Ｈ１８１３１Ｂ；Ｈ１Ｈ１８１３２Ｂ；Ｈ１Ｈ１８１３３Ｂ；Ｈ１Ｈ１８１３４Ｂ；Ｈ１Ｈ１８１３５Ｂ；Ｈ１Ｈ１８１３６Ｂ；Ｈ１Ｈ１８１３７Ｂ；Ｈ１Ｈ１８１３８Ｂ；Ｈ１Ｈ１８１３９Ｂ；Ｈ１Ｈ１８１４０Ｂ；Ｈ１Ｈ１８１４１Ｂ；Ｈ１Ｈ１８１４２Ｂ；Ｈ１Ｈ１８１４３Ｂ；Ｈ１Ｈ１８１４４Ｂ；Ｈ１Ｈ１８１４５Ｂ；Ｈ１Ｈ１８１４６Ｂ；Ｈ１Ｈ１８１４７Ｂ；Ｈ１Ｈ１８１４８Ｂ；Ｈ１Ｈ１８１４９Ｂ；Ｈ１Ｈ１８１５０Ｂ；Ｈ１Ｈ１８１５１Ｂ；Ｈ１Ｈ１８１５２Ｂ；Ｈ１Ｈ１８１５３Ｂ；Ｈ１Ｈ１８１５４Ｂ；Ｈ１Ｈ１８１５５Ｂ；Ｈ１Ｈ１８１５６Ｂ；Ｈ１Ｈ１８１５７Ｂ；Ｈ１Ｈ１８１５８Ｂ；Ｈ１Ｈ１８１５９Ｂ；Ｈ１Ｈ１８１６０Ｂ；Ｈ１Ｈ１８１６１Ｂ；Ｈ１Ｈ１８１６２Ｂ；Ｈ１Ｈ１８１６３Ｂ；Ｈ１Ｈ１８１６４Ｂ；Ｈ１Ｈ１８１６５Ｂ；Ｈ１Ｈ１８１６６Ｂ；Ｈ１Ｈ１８１６７Ｂ；Ｈ１Ｈ１８１６８Ｂ；Ｈ１Ｈ１８１６９Ｂ；Ｈ１Ｈ１８１７０Ｂ；Ｈ１Ｈ１８１７１Ｂ；Ｈ１Ｈ１８１７２Ｂ；Ｈ１Ｈ１８１７３Ｂ；Ｈ１Ｈ１８１７４Ｂ；Ｈ１Ｈ１８１７５Ｂ；Ｈ１Ｈ１８１７６Ｂ；Ｈ１Ｈ１８１７
７Ｂ；Ｈ１Ｈ１８１７８Ｂ；Ｈ１Ｈ１８１７９Ｂ；Ｈ１Ｈ１８１８０Ｂ；Ｈ１Ｈ１８１８１Ｂ；Ｈ１Ｈ１８１８２Ｂ；Ｈ１Ｈ１８１８３Ｂ；Ｈ１Ｈ１８１８４Ｂ；Ｈ１Ｈ１８１８５Ｂ；Ｈ１Ｈ１８１８６Ｂ；Ｈ１Ｈ１８１８７Ｂ；Ｈ１Ｈ１８１８８Ｂ；Ｈ１Ｈ１８１８９Ｂ；Ｈ１Ｈ１８１９０Ｂ；Ｈ１Ｈ１８１９１Ｂ；Ｈ１Ｈ１８１９２Ｂ；Ｈ１Ｈ１８１９３Ｂ；Ｈ１Ｈ１８１９４Ｂ；Ｈ１Ｈ１８１９５Ｂ；Ｈ１Ｈ１８１９６Ｂ；Ｈ１Ｈ１８１９７Ｂ；Ｈ１Ｈ１８１９８Ｂ；Ｈ１Ｈ１８１９９Ｂ；Ｈ１Ｈ１８２００Ｂ；Ｈ１Ｈ１８２０１Ｂ；Ｈ１Ｈ１８２０２Ｂ；Ｈ１Ｈ１８２０３Ｂ；Ｈ１Ｈ１８２０４Ｂ；Ｈ１Ｈ１８２０５Ｂ；Ｈ１Ｈ１８２０６Ｂ；Ｈ１Ｈ１８２０７Ｂ；Ｈ１Ｈ１８２０８Ｂ；Ｈ１Ｈ１８２０９Ｂ；Ｈ１Ｈ１８２１０Ｂ；Ｈ１Ｈ１８２１１Ｂ；Ｈ１Ｈ１８２１２Ｂ；Ｈ１Ｈ１８２１３Ｂ；Ｈ１Ｈ１８２１４Ｂ；Ｈ１Ｈ１８２１６Ｂ；Ｈ１Ｈ１８２１７Ｂ；Ｈ１Ｈ１８２１８Ｂ；Ｈ１Ｈ１８２１９Ｂ；Ｈ１Ｈ１８２２０Ｂ；Ｈ１Ｈ１８２２１Ｂ；Ｈ１Ｈ１８２２２Ｂ；Ｈ１Ｈ１８２２３Ｂ；Ｈ１Ｈ１８２２４Ｂ；Ｈ１Ｈ１８２２５Ｂ；Ｈ１Ｈ１８２２６Ｂ；Ｈ１Ｈ１８２２７Ｂ；Ｈ１Ｈ１８２２８Ｂ；Ｈ１Ｈ１８２２９Ｂ；Ｈ１Ｈ１８２３０Ｂ；Ｈ１Ｈ１８２３１Ｂ；Ｈ１Ｈ１８２３２Ｂ；Ｈ１Ｈ１８２３３Ｂ；Ｈ１Ｈ１８２３４Ｂ；Ｈ１Ｈ１８２３５Ｂ；Ｈ１Ｈ１８２３６Ｂ；Ｈ１Ｈ１８２３７Ｂ；Ｈ１Ｈ１８２３８Ｂ；Ｈ１Ｈ１８２３９Ｂ；Ｈ１Ｈ１８２４０Ｂ；Ｈ１Ｈ１８２４１Ｂ；Ｈ１Ｈ１８２４２Ｂ；Ｈ１Ｈ１８２４３Ｂ；Ｈ１Ｈ１８２４４Ｂ；Ｈ１Ｈ１８２４５Ｂ；Ｈ１Ｈ１８２４６Ｂ；Ｈ１Ｈ１８２４７Ｂ；Ｈ１Ｈ１８２４８Ｂ；Ｈ１Ｈ１８２４９Ｂ；Ｈ１Ｈ１８２５０Ｂ；Ｈ１Ｈ１８２５１Ｂ；Ｈ１Ｈ１８２５２Ｂ；Ｈ１Ｈ１８２５３Ｂ；Ｈ１Ｈ１８２５４Ｂ；Ｈ１Ｈ１８２５５Ｂ；Ｈ１Ｈ１８２５６Ｂ；Ｈ１Ｈ１８２５７Ｂ；Ｈ１Ｈ１８２５８Ｂ；Ｈ１Ｈ１８２５９Ｂ；Ｈ１Ｈ１８２６１Ｂ；Ｈ１Ｈ１８２６２Ｂ；Ｈ１Ｈ１８２６３Ｂ；Ｈ１Ｈ１８２６４Ｂ；Ｈ１Ｈ１８２６５Ｂ；Ｈ１Ｈ１８２６６Ｂ；Ｈ１Ｈ１８２６７Ｂ；Ｈ１Ｈ１８２６８Ｂ；Ｈ１Ｈ１８２６９Ｂ；Ｈ１Ｈ１８２７０Ｂ；Ｈ１Ｈ１８２７１Ｂ；Ｈ１Ｈ１８２７２Ｂ；Ｈ１Ｈ１８２７４Ｂ；Ｈ１Ｈ１８２７５Ｂ；Ｈ１Ｈ１８２７６Ｂ；Ｈ１Ｈ１８２７７Ｂ；Ｈ１Ｈ１８２７８Ｂ；Ｈ１Ｈ１８２７９Ｂ；Ｈ１Ｈ１８２８０Ｂ；Ｈ１Ｈ１８２８１Ｂ；Ｈ１Ｈ１８２８２Ｂ；Ｈ１Ｈ１８２８３Ｂ；Ｈ１Ｈ１８２８４Ｂ；Ｈ１Ｈ１８２８５Ｂ；Ｈ１Ｈ１８２８６Ｂ；Ｈ１Ｈ１８２８７Ｂ；Ｈ１Ｈ１８２８８Ｂ；Ｈ１Ｈ１８２８９Ｂ；Ｈ１Ｈ１８２９０Ｂ；Ｈ１Ｈ１８２９１Ｂ；Ｈ１Ｈ１８２９２Ｂ；Ｈ１Ｈ１８２９３Ｂ；Ｈ１Ｈ１８２９４Ｂ；Ｈ１Ｈ１８２９５Ｂ；Ｈ１Ｈ１８２９７Ｂ；Ｈ１Ｈ１８２９８Ｂ；Ｈ１Ｈ１８２９９Ｂ；Ｈ１Ｈ１８３００Ｂ；Ｈ１Ｈ１８３０１Ｂ；Ｈ１Ｈ１８３０２Ｂ；Ｈ１Ｈ１８３０３Ｂ；Ｈ１Ｈ１８３０４Ｂ；Ｈ１Ｈ１８３０５Ｂ；Ｈ１Ｈ１８３０６Ｂ；Ｈ１Ｈ１８３０７Ｂ；Ｈ１Ｈ１８３０８Ｂ；Ｈ１Ｈ１８３０９Ｂ；Ｈ１Ｈ１８３１０Ｂ；Ｈ１Ｈ１８３１１Ｂ；Ｈ１Ｈ１８３１２Ｂ；Ｈ１Ｈ１８３１３Ｂ；Ｈ１Ｈ１８３１４Ｂ；Ｈ１Ｈ１８３１５Ｂ；Ｈ１Ｈ１８３１６Ｂ；Ｈ１Ｈ１８３１７Ｂ；Ｈ１Ｈ１８３１８Ｂ；Ｈ１Ｈ１８３１９Ｂ；Ｈ１Ｈ１８３２０Ｂ；Ｈ１Ｈ１８３２１Ｂ；Ｈ１Ｈ１８３２２Ｂ；Ｈ１Ｈ１８３２３Ｂ；Ｈ１Ｈ１８３２４Ｂ；Ｈ１Ｈ１８３２５Ｂ；Ｈ１Ｈ１８３２６Ｂ；Ｈ１Ｈ１８３２７Ｂ；Ｈ１Ｈ１８３２８Ｂ；Ｈ１Ｈ１８３２９Ｂ；Ｈ１Ｈ１８３３０Ｂ；Ｈ１Ｈ１８３３１Ｂ；Ｈ１Ｈ１８３３２Ｂ；Ｈ１Ｈ１８３３３Ｂ；Ｈ１Ｈ１８３３４Ｂ；およびＨ１Ｈ１８３３５Ｂからなる群から選択される抗体またはその抗原結合断片である、請求項１９または２０のいずれか１項に記載の組成物またはキット。 Further therapeutic agents consist of regipasivir, sofosbuvir, a combination of regipasivir and sofosbuvir, oseltamivir, zanamivir, ribavirin and interferon-alpha 2b, interferon-alpha 2a, anticancer agents, and antibodies or antigen-binding fragments thereof that specifically bind to influenza HA.群から選択されるメンバー；ならびに／またはＨ１Ｈ１４６１１Ｎ２；Ｈ１Ｈ１４６１２Ｎ２；Ｈ１Ｈ１１７２３Ｐ；Ｈ１Ｈ１１７２９Ｐ；Ｈ１Ｈ１１８２０Ｎ；Ｈ１Ｈ１１８２９Ｎ；Ｈ１Ｈ１１８２９Ｎ２；Ｈ２ａＭ１１８２９Ｎ；Ｈ２Ｍ１１８３０Ｎ；Ｈ１Ｈ１１８３０Ｎ２；Ｈ１Ｈ１１９０３Ｎ；Ｈ１Ｈ１４５７１Ｎ；Ｈ２ａ１４５７１Ｎ；Ｈ１Ｈ１１７０４Ｐ；Ｈ１Ｈ１１７１１Ｐ；Ｈ１Ｈ１１７１４Ｐ；Ｈ１Ｈ１１７１７Ｐ；Ｈ１Ｈ１１７２４Ｐ；Ｈ１Ｈ１１７２７Ｐ；Ｈ１Ｈ１１７３０Ｐ２； Ｈ１Ｈ１１７３１Ｐ２；Ｈ１Ｈ１１７３４Ｐ２；Ｈ１Ｈ１１７３６Ｐ２；Ｈ１Ｈ１１７４２Ｐ２；Ｈ１Ｈ１１７４４Ｐ２；Ｈ１Ｈ１１７４５Ｐ２；Ｈ１Ｈ１１７４７Ｐ２；Ｈ１Ｈ１１７４８Ｐ２；Ｈ１Ｈ１７９５２Ｂ；Ｈ１Ｈ１７９５３Ｂ；Ｈ１Ｈ１７９５４Ｂ；Ｈ１Ｈ１７９５５Ｂ；Ｈ１Ｈ１７９５６Ｂ；Ｈ１Ｈ１７９５７Ｂ；Ｈ１Ｈ１７９５８Ｂ；Ｈ１Ｈ１７９５９Ｂ；Ｈ１Ｈ１７９６０Ｂ；Ｈ１Ｈ１７９６１Ｂ；Ｈ１Ｈ１７９６２Ｂ；Ｈ１Ｈ１７９６３Ｂ；Ｈ１Ｈ１７９６４Ｂ；Ｈ１Ｈ１７９６５Ｂ；Ｈ１Ｈ１７９６６Ｂ；Ｈ１Ｈ１７９６７Ｂ；Ｈ１Ｈ１７９６８Ｂ； H1H17969B; H1H17970B; H1H17971B; H1H17972B; H1H17973B; H1H1797
４Ｂ；Ｈ１Ｈ１７９７５Ｂ；Ｈ１Ｈ１７９７６Ｂ；Ｈ１Ｈ１７９７７Ｂ；Ｈ１Ｈ１７９７８Ｂ；Ｈ１Ｈ１７９７９Ｂ；Ｈ１Ｈ１７９８０Ｂ；Ｈ１Ｈ１７９８１Ｂ；Ｈ１Ｈ１７９８２Ｂ；Ｈ１Ｈ１７９８３Ｂ；Ｈ１Ｈ１７９８４Ｂ；Ｈ１Ｈ１７９８５Ｂ；Ｈ１Ｈ１７９８６Ｂ；Ｈ１Ｈ１７９８７Ｂ；Ｈ１Ｈ１７９８８Ｂ；Ｈ１Ｈ１７９８９Ｂ；Ｈ１Ｈ１７９９０Ｂ；Ｈ１Ｈ１７９９１Ｂ；Ｈ１Ｈ１７９９２Ｂ；Ｈ１Ｈ１７９９３Ｂ；Ｈ１Ｈ１７９９４Ｂ；Ｈ１Ｈ１７９９５Ｂ；Ｈ１Ｈ１７９９６Ｂ；Ｈ１Ｈ１７９９７Ｂ；Ｈ１Ｈ１７９９８Ｂ； Ｈ１Ｈ１７９９９Ｂ；Ｈ１Ｈ１８０００Ｂ；Ｈ１Ｈ１８００１Ｂ；Ｈ１Ｈ１８００２Ｂ；Ｈ１Ｈ１８００３Ｂ；Ｈ１Ｈ１８００４Ｂ；Ｈ１Ｈ１８００５Ｂ；Ｈ１Ｈ１８００６Ｂ；Ｈ１Ｈ１８００７Ｂ；Ｈ１Ｈ１８００８Ｂ；Ｈ１Ｈ１８００９Ｂ；Ｈ１Ｈ１８０１０Ｂ；Ｈ１Ｈ１８０１１Ｂ；Ｈ１Ｈ１８０１２Ｂ；Ｈ１Ｈ１８０１３Ｂ；Ｈ１Ｈ１８０１４Ｂ；Ｈ１Ｈ１８０１５Ｂ；Ｈ１Ｈ１８０１６Ｂ；Ｈ１Ｈ１８０１７Ｂ；Ｈ１Ｈ１８０１８Ｂ；Ｈ１Ｈ１８０１９Ｂ；Ｈ１Ｈ１８０２０Ｂ；Ｈ１Ｈ１８０２１Ｂ；Ｈ１Ｈ１８０２２Ｂ；Ｈ１Ｈ１８０２３Ｂ； Ｈ１Ｈ１８０２４Ｂ；Ｈ１Ｈ１８０２５Ｂ；Ｈ１Ｈ１８０２６Ｂ；Ｈ１Ｈ１８０２７Ｂ；Ｈ１Ｈ１８０２８Ｂ；Ｈ１Ｈ１８０２９Ｂ；Ｈ１Ｈ１８０３０Ｂ；Ｈ１Ｈ１８０３１Ｂ；Ｈ１Ｈ１８０３２Ｂ；Ｈ１Ｈ１８０３３Ｂ；Ｈ１Ｈ１８０３４Ｂ；Ｈ１Ｈ１８０３５Ｂ；Ｈ１Ｈ１８０３７Ｂ；Ｈ１Ｈ１８０３８Ｂ；Ｈ１Ｈ１８０３９Ｂ；Ｈ１Ｈ１８０４０Ｂ；Ｈ１Ｈ１８０４１Ｂ；Ｈ１Ｈ１８０４２Ｂ；Ｈ１Ｈ１８０４３Ｂ；Ｈ１Ｈ１８０４４Ｂ；Ｈ１Ｈ１８０４５Ｂ；Ｈ１Ｈ１８０４６Ｂ；Ｈ１Ｈ１８０４７Ｂ；Ｈ１Ｈ１８０４８Ｂ；Ｈ１Ｈ１８０４９Ｂ； Ｈ１Ｈ１８０５１Ｂ；Ｈ１Ｈ１８０５２Ｂ；Ｈ１Ｈ１８０５３Ｂ；Ｈ１Ｈ１８０５４Ｂ；Ｈ１Ｈ１８０５５Ｂ；Ｈ１Ｈ１８０５６Ｂ；Ｈ１Ｈ１８０５７Ｂ；Ｈ１Ｈ１８０５８Ｂ；Ｈ１Ｈ１８０５９Ｂ；Ｈ１Ｈ１８０６０Ｂ；Ｈ１Ｈ１８０６１Ｂ；Ｈ１Ｈ１８０６２Ｂ；Ｈ１Ｈ１８０６３Ｂ；Ｈ１Ｈ１８０６４Ｂ；Ｈ１Ｈ１８０６５Ｂ；Ｈ１Ｈ１８０６６Ｂ；Ｈ１Ｈ１８０６７Ｂ；Ｈ１Ｈ１８０６８Ｂ；Ｈ１Ｈ１８０６９Ｂ；Ｈ１Ｈ１８０７０Ｂ；Ｈ１Ｈ１８０７１Ｂ；Ｈ１Ｈ１８０７２Ｂ；Ｈ１Ｈ１８０７３Ｂ；Ｈ１Ｈ１８０７４Ｂ；Ｈ１Ｈ１８０７５Ｂ； H1H1807 ６Ｂ；Ｈ１Ｈ１８０７７Ｂ；Ｈ１Ｈ１８０７８Ｂ；Ｈ１Ｈ１８０７９Ｂ；Ｈ１Ｈ１８０８０Ｂ；Ｈ１Ｈ１８０８１Ｂ；Ｈ１Ｈ１８０８２Ｂ；Ｈ１Ｈ１８０８３Ｂ；Ｈ１Ｈ１８０８４Ｂ；Ｈ１Ｈ１８０８５Ｂ；Ｈ１Ｈ１８０８６Ｂ；Ｈ１Ｈ１８０８７Ｂ；Ｈ１Ｈ１８０８８Ｂ；Ｈ１Ｈ１８０８９Ｂ；Ｈ１Ｈ１８０９０Ｂ；Ｈ１Ｈ１８０９１Ｂ；Ｈ１Ｈ１８０９２Ｂ；Ｈ１Ｈ１８０９３Ｂ；Ｈ１Ｈ１８０９４Ｂ；Ｈ１Ｈ１８０９５Ｂ；Ｈ１Ｈ１８０９６Ｂ；Ｈ１Ｈ１８０９７Ｂ；Ｈ１Ｈ１８０９８Ｂ；Ｈ１Ｈ１８０９９Ｂ；Ｈ１Ｈ１８１００Ｂ； Ｈ１Ｈ１８１０１Ｂ；Ｈ１Ｈ１８１０２Ｂ；Ｈ１Ｈ１８１０３Ｂ；Ｈ１Ｈ１８１０４Ｂ；Ｈ１Ｈ１８１０５Ｂ；Ｈ１Ｈ１８１０７Ｂ；Ｈ１Ｈ１８１０８Ｂ；Ｈ１Ｈ１８１０９Ｂ；Ｈ１Ｈ１８１１０Ｂ；Ｈ１Ｈ１８１１１Ｂ；Ｈ１Ｈ１８１１２Ｂ；Ｈ１Ｈ１８１１３Ｂ；Ｈ１Ｈ１８１１４Ｂ；Ｈ１Ｈ１８１１５Ｂ；Ｈ１Ｈ１８１１６Ｂ；Ｈ１Ｈ１８１１７Ｂ；Ｈ１Ｈ１８１１８Ｂ；Ｈ１Ｈ１８１１９Ｂ；Ｈ１Ｈ１８１２０Ｂ；Ｈ１Ｈ１８１２１Ｂ；Ｈ１Ｈ１８１２２Ｂ；Ｈ１Ｈ１８１２３Ｂ；Ｈ１Ｈ１８１２４Ｂ；Ｈ１Ｈ１８１２５Ｂ；Ｈ１Ｈ１８１２６Ｂ； Ｈ１Ｈ１８１２７Ｂ；Ｈ１Ｈ１８１２８Ｂ；Ｈ１Ｈ１８１２９Ｂ；Ｈ１Ｈ１８１３０Ｂ；Ｈ１Ｈ１８１３１Ｂ；Ｈ１Ｈ１８１３２Ｂ；Ｈ１Ｈ１８１３３Ｂ；Ｈ１Ｈ１８１３４Ｂ；Ｈ１Ｈ１８１３５Ｂ；Ｈ１Ｈ１８１３６Ｂ；Ｈ１Ｈ１８１３７Ｂ；Ｈ１Ｈ１８１３８Ｂ；Ｈ１Ｈ１８１３９Ｂ；Ｈ１Ｈ１８１４０Ｂ；Ｈ１Ｈ１８１４１Ｂ；Ｈ１Ｈ１８１４２Ｂ；Ｈ１Ｈ１８１４３Ｂ；Ｈ１Ｈ１８１４４Ｂ；Ｈ１Ｈ１８１４５Ｂ；Ｈ１Ｈ１８１４６Ｂ；Ｈ１Ｈ１８１４７Ｂ；Ｈ１Ｈ１８１４８Ｂ；Ｈ１Ｈ１８１４９Ｂ；Ｈ１Ｈ１８１５０Ｂ；Ｈ１Ｈ１８１５１Ｂ； Ｈ１Ｈ１８１５２Ｂ；Ｈ１Ｈ１８１５３Ｂ；Ｈ１Ｈ１８１５４Ｂ；Ｈ１Ｈ１８１５５Ｂ；Ｈ１Ｈ１８１５６Ｂ；Ｈ１Ｈ１８１５７Ｂ；Ｈ１Ｈ１８１５８Ｂ；Ｈ１Ｈ１８１５９Ｂ；Ｈ１Ｈ１８１６０Ｂ；Ｈ１Ｈ１８１６１Ｂ；Ｈ１Ｈ１８１６２Ｂ；Ｈ１Ｈ１８１６３Ｂ；Ｈ１Ｈ１８１６４Ｂ；Ｈ１Ｈ１８１６５Ｂ；Ｈ１Ｈ１８１６６Ｂ；Ｈ１Ｈ１８１６７Ｂ；Ｈ１Ｈ１８１６８Ｂ；Ｈ１Ｈ１８１６９Ｂ；Ｈ１Ｈ１８１７０Ｂ；Ｈ１Ｈ１８１７１Ｂ；Ｈ１Ｈ１８１７２Ｂ；Ｈ１Ｈ１８１７３Ｂ；Ｈ１Ｈ１８１７４Ｂ；Ｈ１Ｈ１８１７５Ｂ；Ｈ１Ｈ１８１７６Ｂ； H1H1817
７Ｂ；Ｈ１Ｈ１８１７８Ｂ；Ｈ１Ｈ１８１７９Ｂ；Ｈ１Ｈ１８１８０Ｂ；Ｈ１Ｈ１８１８１Ｂ；Ｈ１Ｈ１８１８２Ｂ；Ｈ１Ｈ１８１８３Ｂ；Ｈ１Ｈ１８１８４Ｂ；Ｈ１Ｈ１８１８５Ｂ；Ｈ１Ｈ１８１８６Ｂ；Ｈ１Ｈ１８１８７Ｂ；Ｈ１Ｈ１８１８８Ｂ；Ｈ１Ｈ１８１８９Ｂ；Ｈ１Ｈ１８１９０Ｂ；Ｈ１Ｈ１８１９１Ｂ；Ｈ１Ｈ１８１９２Ｂ；Ｈ１Ｈ１８１９３Ｂ；Ｈ１Ｈ１８１９４Ｂ；Ｈ１Ｈ１８１９５Ｂ；Ｈ１Ｈ１８１９６Ｂ；Ｈ１Ｈ１８１９７Ｂ；Ｈ１Ｈ１８１９８Ｂ；Ｈ１Ｈ１８１９９Ｂ；Ｈ１Ｈ１８２００Ｂ；Ｈ１Ｈ１８２０１Ｂ； Ｈ１Ｈ１８２０２Ｂ；Ｈ１Ｈ１８２０３Ｂ；Ｈ１Ｈ１８２０４Ｂ；Ｈ１Ｈ１８２０５Ｂ；Ｈ１Ｈ１８２０６Ｂ；Ｈ１Ｈ１８２０７Ｂ；Ｈ１Ｈ１８２０８Ｂ；Ｈ１Ｈ１８２０９Ｂ；Ｈ１Ｈ１８２１０Ｂ；Ｈ１Ｈ１８２１１Ｂ；Ｈ１Ｈ１８２１２Ｂ；Ｈ１Ｈ１８２１３Ｂ；Ｈ１Ｈ１８２１４Ｂ；Ｈ１Ｈ１８２１６Ｂ；Ｈ１Ｈ１８２１７Ｂ；Ｈ１Ｈ１８２１８Ｂ；Ｈ１Ｈ１８２１９Ｂ；Ｈ１Ｈ１８２２０Ｂ；Ｈ１Ｈ１８２２１Ｂ；Ｈ１Ｈ１８２２２Ｂ；Ｈ１Ｈ１８２２３Ｂ；Ｈ１Ｈ１８２２４Ｂ；Ｈ１Ｈ１８２２５Ｂ；Ｈ１Ｈ１８２２６Ｂ；Ｈ１Ｈ１８２２７Ｂ； Ｈ１Ｈ１８２２８Ｂ；Ｈ１Ｈ１８２２９Ｂ；Ｈ１Ｈ１８２３０Ｂ；Ｈ１Ｈ１８２３１Ｂ；Ｈ１Ｈ１８２３２Ｂ；Ｈ１Ｈ１８２３３Ｂ；Ｈ１Ｈ１８２３４Ｂ；Ｈ１Ｈ１８２３５Ｂ；Ｈ１Ｈ１８２３６Ｂ；Ｈ１Ｈ１８２３７Ｂ；Ｈ１Ｈ１８２３８Ｂ；Ｈ１Ｈ１８２３９Ｂ；Ｈ１Ｈ１８２４０Ｂ；Ｈ１Ｈ１８２４１Ｂ；Ｈ１Ｈ１８２４２Ｂ；Ｈ１Ｈ１８２４３Ｂ；Ｈ１Ｈ１８２４４Ｂ；Ｈ１Ｈ１８２４５Ｂ；Ｈ１Ｈ１８２４６Ｂ；Ｈ１Ｈ１８２４７Ｂ；Ｈ１Ｈ１８２４８Ｂ；Ｈ１Ｈ１８２４９Ｂ；Ｈ１Ｈ１８２５０Ｂ；Ｈ１Ｈ１８２５１Ｂ；Ｈ１Ｈ１８２５２Ｂ； Ｈ１Ｈ１８２５３Ｂ；Ｈ１Ｈ１８２５４Ｂ；Ｈ１Ｈ１８２５５Ｂ；Ｈ１Ｈ１８２５６Ｂ；Ｈ１Ｈ１８２５７Ｂ；Ｈ１Ｈ１８２５８Ｂ；Ｈ１Ｈ１８２５９Ｂ；Ｈ１Ｈ１８２６１Ｂ；Ｈ１Ｈ１８２６２Ｂ；Ｈ１Ｈ１８２６３Ｂ；Ｈ１Ｈ１８２６４Ｂ；Ｈ１Ｈ１８２６５Ｂ；Ｈ１Ｈ１８２６６Ｂ；Ｈ１Ｈ１８２６７Ｂ；Ｈ１Ｈ１８２６８Ｂ；Ｈ１Ｈ１８２６９Ｂ；Ｈ１Ｈ１８２７０Ｂ；Ｈ１Ｈ１８２７１Ｂ；Ｈ１Ｈ１８２７２Ｂ；Ｈ１Ｈ１８２７４Ｂ；Ｈ１Ｈ１８２７５Ｂ；Ｈ１Ｈ１８２７６Ｂ；Ｈ１Ｈ１８２７７Ｂ；Ｈ１Ｈ１８２７８Ｂ；Ｈ１Ｈ１８２７９Ｂ； H1H1828 ０Ｂ；Ｈ１Ｈ１８２８１Ｂ；Ｈ１Ｈ１８２８２Ｂ；Ｈ１Ｈ１８２８３Ｂ；Ｈ１Ｈ１８２８４Ｂ；Ｈ１Ｈ１８２８５Ｂ；Ｈ１Ｈ１８２８６Ｂ；Ｈ１Ｈ１８２８７Ｂ；Ｈ１Ｈ１８２８８Ｂ；Ｈ１Ｈ１８２８９Ｂ；Ｈ１Ｈ１８２９０Ｂ；Ｈ１Ｈ１８２９１Ｂ；Ｈ１Ｈ１８２９２Ｂ；Ｈ１Ｈ１８２９３Ｂ；Ｈ１Ｈ１８２９４Ｂ；Ｈ１Ｈ１８２９５Ｂ；Ｈ１Ｈ１８２９７Ｂ；Ｈ１Ｈ１８２９８Ｂ；Ｈ１Ｈ１８２９９Ｂ；Ｈ１Ｈ１８３００Ｂ；Ｈ１Ｈ１８３０１Ｂ；Ｈ１Ｈ１８３０２Ｂ；Ｈ１Ｈ１８３０３Ｂ；Ｈ１Ｈ１８３０４Ｂ；Ｈ１Ｈ１８３０５Ｂ； Ｈ１Ｈ１８３０６Ｂ；Ｈ１Ｈ１８３０７Ｂ；Ｈ１Ｈ１８３０８Ｂ；Ｈ１Ｈ１８３０９Ｂ；Ｈ１Ｈ１８３１０Ｂ；Ｈ１Ｈ１８３１１Ｂ；Ｈ１Ｈ１８３１２Ｂ；Ｈ１Ｈ１８３１３Ｂ；Ｈ１Ｈ１８３１４Ｂ；Ｈ１Ｈ１８３１５Ｂ；Ｈ１Ｈ１８３１６Ｂ；Ｈ１Ｈ１８３１７Ｂ；Ｈ１Ｈ１８３１８Ｂ；Ｈ１Ｈ１８３１９Ｂ；Ｈ１Ｈ１８３２０Ｂ；Ｈ１Ｈ１８３２１Ｂ；Ｈ１Ｈ１８３２２Ｂ；Ｈ１Ｈ１８３２３Ｂ；Ｈ１Ｈ１８３２４Ｂ；Ｈ１Ｈ１８３２５Ｂ；Ｈ１Ｈ１８３２６Ｂ；Ｈ１Ｈ１８３２７Ｂ；Ｈ１Ｈ１８３２８Ｂ；Ｈ１Ｈ１８３２９Ｂ；Ｈ１Ｈ１８３３０Ｂ； The composition or kit according to any one of claims 19 or 20, which is an antibody or antigen-binding fragment thereof selected from the group consisting of H1H18331B; H1H183332B; H1H183333B; H1H18334B; and H1H18335B. 請求項１～９、１４、１５および１９～２２のいずれか１項に記載の抗原結合タンパク質、ポリぺプチド、もしくは組成物を含む容器または注入デバイス。 A container or infusion device comprising the antigen-binding protein, polypeptide, or composition according to any one of claims 1-9, 14, 15 and 19-22. 癌またはインフルエンザウイルス、コロナウイルス、ＳＡＲＳ－Ｃｏウイルス、ＭＥＲＳ－Ｃｏウイルス、パラインフルエンザウイルス、ヒトメタニューモウイルスもしくはＣ型肝炎ウイルス（ＨＣＶ）による感染を治療または予防するための、請求項１～９のいずれか１項に記載の抗原結合タンパク質を含む医薬組成物であって、該医薬組成物の治療有効量を、それを必要としている対象に投与することを特徴とする、前記医薬組成物。 Claims 1-9 for treating or preventing infection with cancer or influenza virus, corona virus, SARS-Co virus, MERS-Co virus, parainfluenza virus, human metapneumovirus or hepatitis C virus (HCV). The pharmaceutical composition comprising the antigen-binding protein according to any one of the above, which comprises administering a therapeutically effective amount of the pharmaceutical composition to a subject in need thereof. 前立腺癌、結腸癌、肺癌、膵臓癌、尿路癌、乳癌、卵巣癌、前立腺腺癌、腎細胞癌、結腸直腸腺癌、肺腺癌、肺扁平上皮癌および／もしくは胸膜中皮腫である癌を治療または予防する、請求項２４に記載の医薬組成物。 Prostate cancer, colon cancer, lung cancer, pancreatic cancer, urinary tract cancer, breast cancer, ovarian cancer, prostate adenocarcinoma, renal cell carcinoma, colorectal adenocarcinoma, lung adenocarcinoma, squamous cell carcinoma of the lung and / or pleural dermatomas. 24. The pharmaceutical composition according to claim 24, which treats or prevents cancer. 対象は１つまたはそれ以上のさらなる治療剤を投与されることを特徴とする、請求項２４または２５に記載の医薬組成物。 25. The pharmaceutical composition of claim 24 or 25, wherein the subject is administered one or more additional therapeutic agents. 対象は、抗ウイルス薬またはワクチンである１つもしくはそれ以上のさらなる治療剤を投与されることを特徴とする、請求項２６に記載の医薬組成物。 26. The pharmaceutical composition of claim 26, wherein the subject is administered one or more additional therapeutic agents that are antiviral agents or vaccines. レジパスビル、ソホスブビル、レジパスビルとソホスブビルの組合せ、オセルタミビル、ザナミビル、リバビリンおよびインターフェロン－アルファ２ｂ、インターフェロン－アルファ２ａ、ならびにインフルエンザＨＡに特異的に結合する抗体もしくはその抗原結合断片からなる群から選択されるメンバー；ならびに／またはＨ１Ｈ１４６１１Ｎ２；Ｈ１Ｈ１４６１２Ｎ２；Ｈ１Ｈ１１７２３Ｐ；Ｈ１Ｈ１１７２９Ｐ；Ｈ１Ｈ１１８２０Ｎ；Ｈ１Ｈ１１８２９Ｎ；Ｈ１Ｈ１１８２９Ｎ２；Ｈ２ａＭ１１８２９Ｎ；Ｈ２Ｍ１１８３０Ｎ；Ｈ１Ｈ１１８３０Ｎ２；Ｈ１Ｈ１１９０３Ｎ；Ｈ１Ｈ１４５７１Ｎ；Ｈ２ａ１４５７１Ｎ；Ｈ１Ｈ１１７０４Ｐ；Ｈ１Ｈ１１７１１Ｐ；Ｈ１Ｈ１１７１４Ｐ；Ｈ１Ｈ１１７１７Ｐ；Ｈ１Ｈ１１７２４Ｐ；Ｈ１Ｈ１１７２７Ｐ；Ｈ１Ｈ１１７３０Ｐ２；Ｈ１Ｈ１１７３１Ｐ２；Ｈ１Ｈ１１７３４Ｐ２；Ｈ１Ｈ１１７３６Ｐ２；Ｈ１Ｈ１１７４２Ｐ２；Ｈ１Ｈ１１７４４Ｐ２；Ｈ１Ｈ１１７４５Ｐ２；Ｈ１Ｈ１１７４７Ｐ２；Ｈ１Ｈ１１７４８Ｐ２；Ｈ１Ｈ１７９５２Ｂ；Ｈ１Ｈ１７９５３Ｂ；Ｈ１Ｈ１７９５４Ｂ；Ｈ１Ｈ１７９５５Ｂ；Ｈ１Ｈ１７９５６Ｂ；Ｈ１Ｈ１７９５７Ｂ；Ｈ１Ｈ１７９５８Ｂ；Ｈ１Ｈ１７９５９Ｂ；Ｈ１Ｈ１７９６０Ｂ；Ｈ１Ｈ１７９６１Ｂ；Ｈ１Ｈ１７９６２Ｂ；Ｈ１Ｈ１７９６３Ｂ；Ｈ１Ｈ１７９６４Ｂ；Ｈ１Ｈ１７９６５Ｂ；Ｈ１Ｈ１７９６６Ｂ；Ｈ１Ｈ１７９６７Ｂ；Ｈ１Ｈ１７９６８Ｂ；Ｈ１Ｈ１７９６９Ｂ；Ｈ１Ｈ１７９７０Ｂ；Ｈ１Ｈ１７９７１Ｂ；Ｈ１Ｈ１７９７２Ｂ；Ｈ１Ｈ１７９７３Ｂ；Ｈ１Ｈ１７９７４Ｂ；Ｈ１Ｈ１７９７５Ｂ；Ｈ１Ｈ１７９７６Ｂ；Ｈ１Ｈ１７９７７Ｂ；Ｈ１Ｈ１７９７８Ｂ；Ｈ１Ｈ１７９７９Ｂ；Ｈ１Ｈ１７９８０Ｂ；Ｈ１Ｈ１７９８１Ｂ；Ｈ１Ｈ１７９８２Ｂ；Ｈ１Ｈ１７９８３Ｂ；Ｈ１Ｈ１７９８４Ｂ；Ｈ１Ｈ１７９８５Ｂ；Ｈ１Ｈ１７９８６Ｂ；Ｈ１Ｈ１７９８７Ｂ；Ｈ１Ｈ１７９８８Ｂ；Ｈ１Ｈ１７９８９Ｂ；Ｈ１Ｈ１７９９０Ｂ；Ｈ１Ｈ１７９９１Ｂ；Ｈ１Ｈ１７９９２Ｂ；Ｈ１Ｈ１７９９３Ｂ；Ｈ１Ｈ１７９９４Ｂ；Ｈ１Ｈ１７９９５Ｂ；Ｈ１Ｈ１７９９６Ｂ；Ｈ１Ｈ１７９９７Ｂ；Ｈ１Ｈ１７９９８Ｂ；Ｈ１Ｈ１７９９９Ｂ；Ｈ１Ｈ１８０００Ｂ；Ｈ１Ｈ１８００１Ｂ；Ｈ１Ｈ１８００２Ｂ；Ｈ１Ｈ１８００３Ｂ；Ｈ１Ｈ１８００４Ｂ；Ｈ１Ｈ１８００５Ｂ；Ｈ１Ｈ１８００６Ｂ；Ｈ１Ｈ１８００７Ｂ；Ｈ１Ｈ１８００８Ｂ；Ｈ１Ｈ１８００９Ｂ；Ｈ１Ｈ１８０１０Ｂ；Ｈ１Ｈ１８０１１Ｂ；Ｈ１Ｈ１８０１２Ｂ；Ｈ１Ｈ１８０１３Ｂ；Ｈ１Ｈ１８０１４Ｂ；Ｈ１Ｈ１８０１５Ｂ；Ｈ１Ｈ１８０１６Ｂ；Ｈ１Ｈ１８０１７Ｂ；Ｈ１Ｈ１８０１８Ｂ；Ｈ１Ｈ１８０１９Ｂ；Ｈ１Ｈ１８０２０Ｂ；Ｈ１Ｈ１８０２１Ｂ；Ｈ１Ｈ１８０２２Ｂ；Ｈ１Ｈ１８０２３Ｂ；Ｈ１Ｈ１８０２４Ｂ；Ｈ１Ｈ１８０２５Ｂ；Ｈ１Ｈ１８０２６Ｂ；Ｈ１Ｈ１８０２７Ｂ；Ｈ１Ｈ１８０２８Ｂ；Ｈ１Ｈ１８０２９Ｂ；Ｈ１Ｈ１８０３０Ｂ；Ｈ１Ｈ１８０３１Ｂ；Ｈ１Ｈ１８０３２Ｂ；Ｈ１Ｈ１８０３３Ｂ；Ｈ１Ｈ１８０３４Ｂ；Ｈ１Ｈ１８０３５Ｂ；Ｈ１Ｈ１８０３７Ｂ；Ｈ１Ｈ１８０３８Ｂ；Ｈ１Ｈ１８０３９Ｂ；Ｈ１Ｈ１８０４０Ｂ；Ｈ１Ｈ１８０４１Ｂ；Ｈ１Ｈ１８０４２Ｂ；Ｈ１Ｈ１８０４３Ｂ；Ｈ１Ｈ１８０４４Ｂ；Ｈ１Ｈ１８０４５Ｂ；Ｈ１Ｈ１８０４６Ｂ；Ｈ１Ｈ１８０４７Ｂ；Ｈ１Ｈ１８０４８Ｂ；Ｈ１Ｈ１８０４９Ｂ；Ｈ１Ｈ１８０５１Ｂ；Ｈ１Ｈ１８０５２Ｂ；Ｈ１Ｈ１８０５３Ｂ；Ｈ１Ｈ１８０５４Ｂ；Ｈ１Ｈ１８０５５Ｂ；Ｈ１Ｈ１８０５６Ｂ；Ｈ１Ｈ１８０５７Ｂ；Ｈ１Ｈ１８０５８Ｂ；Ｈ１Ｈ１８０５９Ｂ；Ｈ１Ｈ１８０６０Ｂ；Ｈ１Ｈ１８０６１Ｂ；Ｈ１Ｈ１８０６２Ｂ；Ｈ１Ｈ１８０６３Ｂ；Ｈ１Ｈ１８０６４Ｂ；Ｈ１Ｈ１８０６５
Ｂ；Ｈ１Ｈ１８０６６Ｂ；Ｈ１Ｈ１８０６７Ｂ；Ｈ１Ｈ１８０６８Ｂ；Ｈ１Ｈ１８０６９Ｂ；Ｈ１Ｈ１８０７０Ｂ；Ｈ１Ｈ１８０７１Ｂ；Ｈ１Ｈ１８０７２Ｂ；Ｈ１Ｈ１８０７３Ｂ；Ｈ１Ｈ１８０７４Ｂ；Ｈ１Ｈ１８０７５Ｂ；Ｈ１Ｈ１８０７６Ｂ；Ｈ１Ｈ１８０７７Ｂ；Ｈ１Ｈ１８０７８Ｂ；Ｈ１Ｈ１８０７９Ｂ；Ｈ１Ｈ１８０８０Ｂ；Ｈ１Ｈ１８０８１Ｂ；Ｈ１Ｈ１８０８２Ｂ；Ｈ１Ｈ１８０８３Ｂ；Ｈ１Ｈ１８０８４Ｂ；Ｈ１Ｈ１８０８５Ｂ；Ｈ１Ｈ１８０８６Ｂ；Ｈ１Ｈ１８０８７Ｂ；Ｈ１Ｈ１８０８８Ｂ；Ｈ１Ｈ１８０８９Ｂ；Ｈ１Ｈ１８０９０Ｂ；Ｈ１Ｈ１８０９１Ｂ；Ｈ１Ｈ１８０９２Ｂ；Ｈ１Ｈ１８０９３Ｂ；Ｈ１Ｈ１８０９４Ｂ；Ｈ１Ｈ１８０９５Ｂ；Ｈ１Ｈ１８０９６Ｂ；Ｈ１Ｈ１８０９７Ｂ；Ｈ１Ｈ１８０９８Ｂ；Ｈ１Ｈ１８０９９Ｂ；Ｈ１Ｈ１８１００Ｂ；Ｈ１Ｈ１８１０１Ｂ；Ｈ１Ｈ１８１０２Ｂ；Ｈ１Ｈ１８１０３Ｂ；Ｈ１Ｈ１８１０４Ｂ；Ｈ１Ｈ１８１０５Ｂ；Ｈ１Ｈ１８１０７Ｂ；Ｈ１Ｈ１８１０８Ｂ；Ｈ１Ｈ１８１０９Ｂ；Ｈ１Ｈ１８１１０Ｂ；Ｈ１Ｈ１８１１１Ｂ；Ｈ１Ｈ１８１１２Ｂ；Ｈ１Ｈ１８１１３Ｂ；Ｈ１Ｈ１８１１４Ｂ；Ｈ１Ｈ１８１１５Ｂ；Ｈ１Ｈ１８１１６Ｂ；Ｈ１Ｈ１８１１７Ｂ；Ｈ１Ｈ１８１１８Ｂ；Ｈ１Ｈ１８１１９Ｂ；Ｈ１Ｈ１８１２０Ｂ；Ｈ１Ｈ１８１２１Ｂ；Ｈ１Ｈ１８１２２Ｂ；Ｈ１Ｈ１８１２３Ｂ；Ｈ１Ｈ１８１２４Ｂ；Ｈ１Ｈ１８１２５Ｂ；Ｈ１Ｈ１８１２６Ｂ；Ｈ１Ｈ１８１２７Ｂ；Ｈ１Ｈ１８１２８Ｂ；Ｈ１Ｈ１８１２９Ｂ；Ｈ１Ｈ１８１３０Ｂ；Ｈ１Ｈ１８１３１Ｂ；Ｈ１Ｈ１８１３２Ｂ；Ｈ１Ｈ１８１３３Ｂ；Ｈ１Ｈ１８１３４Ｂ；Ｈ１Ｈ１８１３５Ｂ；Ｈ１Ｈ１８１３６Ｂ；Ｈ１Ｈ１８１３７Ｂ；Ｈ１Ｈ１８１３８Ｂ；Ｈ１Ｈ１８１３９Ｂ；Ｈ１Ｈ１８１４０Ｂ；Ｈ１Ｈ１８１４１Ｂ；Ｈ１Ｈ１８１４２Ｂ；Ｈ１Ｈ１８１４３Ｂ；Ｈ１Ｈ１８１４４Ｂ；Ｈ１Ｈ１８１４５Ｂ；Ｈ１Ｈ１８１４６Ｂ；Ｈ１Ｈ１８１４７Ｂ；Ｈ１Ｈ１８１４８Ｂ；Ｈ１Ｈ１８１４９Ｂ；Ｈ１Ｈ１８１５０Ｂ；Ｈ１Ｈ１８１５１Ｂ；Ｈ１Ｈ１８１５２Ｂ；Ｈ１Ｈ１８１５３Ｂ；Ｈ１Ｈ１８１５４Ｂ；Ｈ１Ｈ１８１５５Ｂ；Ｈ１Ｈ１８１５６Ｂ；Ｈ１Ｈ１８１５７Ｂ；Ｈ１Ｈ１８１５８Ｂ；Ｈ１Ｈ１８１５９Ｂ；Ｈ１Ｈ１８１６０Ｂ；Ｈ１Ｈ１８１６１Ｂ；Ｈ１Ｈ１８１６２Ｂ；Ｈ１Ｈ１８１６３Ｂ；Ｈ１Ｈ１８１６４Ｂ；Ｈ１Ｈ１８１６５Ｂ；Ｈ１Ｈ１８１６６Ｂ；Ｈ１Ｈ１８１６７Ｂ；Ｈ１Ｈ１８１６８Ｂ；Ｈ１Ｈ１８１６９Ｂ；Ｈ１Ｈ１８１７０Ｂ；Ｈ１Ｈ１８１７１Ｂ；Ｈ１Ｈ１８１７２Ｂ；Ｈ１Ｈ１８１７３Ｂ；Ｈ１Ｈ１８１７４Ｂ；Ｈ１Ｈ１８１７５Ｂ；Ｈ１Ｈ１８１７６Ｂ；Ｈ１Ｈ１８１７７Ｂ；Ｈ１Ｈ１８１７８Ｂ；Ｈ１Ｈ１８１７９Ｂ；Ｈ１Ｈ１８１８０Ｂ；Ｈ１Ｈ１８１８１Ｂ；Ｈ１Ｈ１８１８２Ｂ；Ｈ１Ｈ１８１８３Ｂ；Ｈ１Ｈ１８１８４Ｂ；Ｈ１Ｈ１８１８５Ｂ；Ｈ１Ｈ１８１８６Ｂ；Ｈ１Ｈ１８１８７Ｂ；Ｈ１Ｈ１８１８８Ｂ；Ｈ１Ｈ１８１８９Ｂ；Ｈ１Ｈ１８１９０Ｂ；Ｈ１Ｈ１８１９１Ｂ；Ｈ１Ｈ１８１９２Ｂ；Ｈ１Ｈ１８１９３Ｂ；Ｈ１Ｈ１８１９４Ｂ；Ｈ１Ｈ１８１９５Ｂ；Ｈ１Ｈ１８１９６Ｂ；Ｈ１Ｈ１８１９７Ｂ；Ｈ１Ｈ１８１９８Ｂ；Ｈ１Ｈ１８１９９Ｂ；Ｈ１Ｈ１８２００Ｂ；Ｈ１Ｈ１８２０１Ｂ；Ｈ１Ｈ１８２０２Ｂ；Ｈ１Ｈ１８２０３Ｂ；Ｈ１Ｈ１８２０４Ｂ；Ｈ１Ｈ１８２０５Ｂ；Ｈ１Ｈ１８２０６Ｂ；Ｈ１Ｈ１８２０７Ｂ；Ｈ１Ｈ１８２０８Ｂ；Ｈ１Ｈ１８２０９Ｂ；Ｈ１Ｈ１８２１０Ｂ；Ｈ１Ｈ１８２１１Ｂ；Ｈ１Ｈ１８２１２Ｂ；Ｈ１Ｈ１８２１３Ｂ；Ｈ１Ｈ１８２１４Ｂ；Ｈ１Ｈ１８２１６Ｂ；Ｈ１Ｈ１８２１７Ｂ；Ｈ１Ｈ１８２１８Ｂ；Ｈ１Ｈ１８２１９Ｂ；Ｈ１Ｈ１８２２０Ｂ；Ｈ１Ｈ１８２２１Ｂ；Ｈ１Ｈ１８２２２Ｂ；Ｈ１Ｈ１８２２３Ｂ；Ｈ１Ｈ１８２２４Ｂ；Ｈ１Ｈ１８２２５Ｂ；Ｈ１Ｈ１８２２６Ｂ；Ｈ１Ｈ１８２２７Ｂ；Ｈ１Ｈ１８２２８Ｂ；Ｈ１Ｈ１８２２９Ｂ；Ｈ１Ｈ１８２３０Ｂ；Ｈ１Ｈ１８２３１Ｂ；Ｈ１Ｈ１８２３２Ｂ；Ｈ１Ｈ１８２３３Ｂ；Ｈ１Ｈ１８２３４Ｂ；Ｈ１Ｈ１８２３５Ｂ；Ｈ１Ｈ１８２３６Ｂ；Ｈ１Ｈ１８２３７Ｂ；Ｈ１Ｈ１８２３８Ｂ；Ｈ１Ｈ１８２３９Ｂ；Ｈ１Ｈ１８２４０Ｂ；Ｈ１Ｈ１８２４１Ｂ；Ｈ１Ｈ１８２４２Ｂ；Ｈ１Ｈ１８２４３Ｂ；Ｈ１Ｈ１８２４４Ｂ；Ｈ１Ｈ１８２４５Ｂ；Ｈ１Ｈ１８２４６Ｂ；Ｈ１Ｈ１８２４７Ｂ；Ｈ１Ｈ１８２４８Ｂ；Ｈ１Ｈ１８２４９Ｂ；Ｈ１Ｈ１８２５０Ｂ；Ｈ１Ｈ１８２５１Ｂ；Ｈ１Ｈ１８２５２Ｂ；Ｈ１Ｈ１８２５３Ｂ；Ｈ１Ｈ１８２５４Ｂ；Ｈ１Ｈ１８２５５Ｂ；Ｈ１Ｈ１８２５６Ｂ；Ｈ１Ｈ１８２５７Ｂ；Ｈ１Ｈ１８２５８Ｂ；Ｈ１Ｈ１８２５９Ｂ；Ｈ１Ｈ１８２６１Ｂ；Ｈ１Ｈ１８２６２Ｂ；Ｈ１Ｈ１８２６３Ｂ；Ｈ１Ｈ１８２６４Ｂ；Ｈ１Ｈ１８２６５Ｂ；Ｈ１Ｈ１８２６６Ｂ；Ｈ１Ｈ１８２６７Ｂ；Ｈ１Ｈ１８２６８
Ｂ；Ｈ１Ｈ１８２６９Ｂ；Ｈ１Ｈ１８２７０Ｂ；Ｈ１Ｈ１８２７１Ｂ；Ｈ１Ｈ１８２７２Ｂ；Ｈ１Ｈ１８２７４Ｂ；Ｈ１Ｈ１８２７５Ｂ；Ｈ１Ｈ１８２７６Ｂ；Ｈ１Ｈ１８２７７Ｂ；Ｈ１Ｈ１８２７８Ｂ；Ｈ１Ｈ１８２７９Ｂ；Ｈ１Ｈ１８２８０Ｂ；Ｈ１Ｈ１８２８１Ｂ；Ｈ１Ｈ１８２８２Ｂ；Ｈ１Ｈ１８２８３Ｂ；Ｈ１Ｈ１８２８４Ｂ；Ｈ１Ｈ１８２８５Ｂ；Ｈ１Ｈ１８２８６Ｂ；Ｈ１Ｈ１８２８７Ｂ；Ｈ１Ｈ１８２８８Ｂ；Ｈ１Ｈ１８２８９Ｂ；Ｈ１Ｈ１８２９０Ｂ；Ｈ１Ｈ１８２９１Ｂ；Ｈ１Ｈ１８２９２Ｂ；Ｈ１Ｈ１８２９３Ｂ；Ｈ１Ｈ１８２９４Ｂ；Ｈ１Ｈ１８２９５Ｂ；Ｈ１Ｈ１８２９７Ｂ；Ｈ１Ｈ１８２９８Ｂ；Ｈ１Ｈ１８２９９Ｂ；Ｈ１Ｈ１８３００Ｂ；Ｈ１Ｈ１８３０１Ｂ；Ｈ１Ｈ１８３０２Ｂ；Ｈ１Ｈ１８３０３Ｂ；Ｈ１Ｈ１８３０４Ｂ；Ｈ１Ｈ１８３０５Ｂ；Ｈ１Ｈ１８３０６Ｂ；Ｈ１Ｈ１８３０７Ｂ；Ｈ１Ｈ１８３０８Ｂ；Ｈ１Ｈ１８３０９Ｂ；Ｈ１Ｈ１８３１０Ｂ；Ｈ１Ｈ１８３１１Ｂ；Ｈ１Ｈ１８３１２Ｂ；Ｈ１Ｈ１８３１３Ｂ；Ｈ１Ｈ１８３１４Ｂ；Ｈ１Ｈ１８３１５Ｂ；Ｈ１Ｈ１８３１６Ｂ；Ｈ１Ｈ１８３１７Ｂ；Ｈ１Ｈ１８３１８Ｂ；Ｈ１Ｈ１８３１９Ｂ；Ｈ１Ｈ１８３２０Ｂ；Ｈ１Ｈ１８３２１Ｂ；Ｈ１Ｈ１８３２２Ｂ；Ｈ１Ｈ１８３２３Ｂ；Ｈ１Ｈ１８３２４Ｂ；Ｈ１Ｈ１８３２５Ｂ；Ｈ１Ｈ１８３２６Ｂ；Ｈ１Ｈ１８３２７Ｂ；Ｈ１Ｈ１８３２８Ｂ；Ｈ１Ｈ１８３２９Ｂ；Ｈ１Ｈ１８３３０Ｂ；Ｈ１Ｈ１８３３１Ｂ；Ｈ１Ｈ１８３３２Ｂ；Ｈ１Ｈ１８３３３Ｂ；Ｈ１Ｈ１８３３４Ｂ；およびＨ１Ｈ１８３３５Ｂからなる群から選択される抗体もしくはその抗原結合断片である１つまたはそれ以上のさらなる治療剤を対象に投与することを特徴とする、請求項２４または２５に記載の医薬組成物。 Members selected from the group consisting of ledipasvir, sofosbuvir, combination of ledipasvir and sofosbuvir, oseltamivir, zanamivir, ribavirin and interferon-alpha 2b, interferon-alpha 2a, and antibodies or antigen-binding fragments thereof that specifically bind to influenza HA;ならびに／またはＨ１Ｈ１４６１１Ｎ２；Ｈ１Ｈ１４６１２Ｎ２；Ｈ１Ｈ１１７２３Ｐ；Ｈ１Ｈ１１７２９Ｐ；Ｈ１Ｈ１１８２０Ｎ；Ｈ１Ｈ１１８２９Ｎ；Ｈ１Ｈ１１８２９Ｎ２；Ｈ２ａＭ１１８２９Ｎ；Ｈ２Ｍ１１８３０Ｎ；Ｈ１Ｈ１１８３０Ｎ２；Ｈ１Ｈ１１９０３Ｎ；Ｈ１Ｈ１４５７１Ｎ；Ｈ２ａ１４５７１Ｎ；Ｈ１Ｈ１１７０４Ｐ；Ｈ１Ｈ１１７１１Ｐ；Ｈ１Ｈ１１７１４Ｐ；Ｈ１Ｈ１１７１７Ｐ；Ｈ１Ｈ１１７２４Ｐ；Ｈ１Ｈ１１７２７Ｐ；Ｈ１Ｈ１１７３０Ｐ２；Ｈ１Ｈ１１７３１Ｐ２；Ｈ１Ｈ１１７３４Ｐ２；Ｈ１Ｈ１１７３６Ｐ２；Ｈ１Ｈ１１７４２Ｐ２ ；Ｈ１Ｈ１１７４４Ｐ２；Ｈ１Ｈ１１７４５Ｐ２；Ｈ１Ｈ１１７４７Ｐ２；Ｈ１Ｈ１１７４８Ｐ２；Ｈ１Ｈ１７９５２Ｂ；Ｈ１Ｈ１７９５３Ｂ；Ｈ１Ｈ１７９５４Ｂ；Ｈ１Ｈ１７９５５Ｂ；Ｈ１Ｈ１７９５６Ｂ；Ｈ１Ｈ１７９５７Ｂ；Ｈ１Ｈ１７９５８Ｂ；Ｈ１Ｈ１７９５９Ｂ；Ｈ１Ｈ１７９６０Ｂ；Ｈ１Ｈ１７９６１Ｂ；Ｈ１Ｈ１７９６２Ｂ；Ｈ１Ｈ１７９６３Ｂ；Ｈ１Ｈ１７９６４Ｂ；Ｈ１Ｈ１７９６５Ｂ；Ｈ１Ｈ１７９６６Ｂ；Ｈ１Ｈ１７９６７Ｂ；Ｈ１Ｈ１７９６８Ｂ；Ｈ１Ｈ１７９６９Ｂ；Ｈ１Ｈ１７９７０Ｂ；Ｈ１Ｈ１７９７１Ｂ；Ｈ１Ｈ１７９７２Ｂ ；Ｈ１Ｈ１７９７３Ｂ；Ｈ１Ｈ１７９７４Ｂ；Ｈ１Ｈ１７９７５Ｂ；Ｈ１Ｈ１７９７６Ｂ；Ｈ１Ｈ１７９７７Ｂ；Ｈ１Ｈ１７９７８Ｂ；Ｈ１Ｈ１７９７９Ｂ；Ｈ１Ｈ１７９８０Ｂ；Ｈ１Ｈ１７９８１Ｂ；Ｈ１Ｈ１７９８２Ｂ；Ｈ１Ｈ１７９８３Ｂ；Ｈ１Ｈ１７９８４Ｂ；Ｈ１Ｈ１７９８５Ｂ；Ｈ１Ｈ１７９８６Ｂ；Ｈ１Ｈ１７９８７Ｂ；Ｈ１Ｈ１７９８８Ｂ；Ｈ１Ｈ１７９８９Ｂ；Ｈ１Ｈ１７９９０Ｂ；Ｈ１Ｈ１７９９１Ｂ；Ｈ１Ｈ１７９９２Ｂ；Ｈ１Ｈ１７９９３Ｂ；Ｈ１Ｈ１７９９４Ｂ；Ｈ１Ｈ１７９９５Ｂ；Ｈ１Ｈ１７９９６Ｂ；Ｈ１Ｈ１７９９７Ｂ H1H17998B; H1H1799B; H1H18000B; H1H18001B; H1H180002B; H1H18003B; H1H18004B; H1H18005B; H1H18006B; H1H18007B ；Ｈ１Ｈ１８００８Ｂ；Ｈ１Ｈ１８００９Ｂ；Ｈ１Ｈ１８０１０Ｂ；Ｈ１Ｈ１８０１１Ｂ；Ｈ１Ｈ１８０１２Ｂ；Ｈ１Ｈ１８０１３Ｂ；Ｈ１Ｈ１８０１４Ｂ；Ｈ１Ｈ１８０１５Ｂ；Ｈ１Ｈ１８０１６Ｂ；Ｈ１Ｈ１８０１７Ｂ；Ｈ１Ｈ１８０１８Ｂ；Ｈ１Ｈ１８０１９Ｂ；Ｈ１Ｈ１８０２０Ｂ；Ｈ１Ｈ１８０２１Ｂ；Ｈ１Ｈ１８０２２Ｂ；Ｈ１Ｈ１８０２３Ｂ；Ｈ１Ｈ１８０２４Ｂ；Ｈ１Ｈ１８０２５Ｂ；Ｈ１Ｈ１８０２６Ｂ；Ｈ１Ｈ１８０２７Ｂ；Ｈ１Ｈ１８０２８Ｂ；Ｈ１Ｈ１８０２９Ｂ；Ｈ１Ｈ１８０３０Ｂ；Ｈ１Ｈ１８０３１Ｂ；Ｈ１Ｈ１８０３２Ｂ ；Ｈ１Ｈ１８０３３Ｂ；Ｈ１Ｈ１８０３４Ｂ；Ｈ１Ｈ１８０３５Ｂ；Ｈ１Ｈ１８０３７Ｂ；Ｈ１Ｈ１８０３８Ｂ；Ｈ１Ｈ１８０３９Ｂ；Ｈ１Ｈ１８０４０Ｂ；Ｈ１Ｈ１８０４１Ｂ；Ｈ１Ｈ１８０４２Ｂ；Ｈ１Ｈ１８０４３Ｂ；Ｈ１Ｈ１８０４４Ｂ；Ｈ１Ｈ１８０４５Ｂ；Ｈ１Ｈ１８０４６Ｂ；Ｈ１Ｈ１８０４７Ｂ；Ｈ１Ｈ１８０４８Ｂ；Ｈ１Ｈ１８０４９Ｂ；Ｈ１Ｈ１８０５１Ｂ；Ｈ１Ｈ１８０５２Ｂ；Ｈ１Ｈ１８０５３Ｂ；Ｈ１Ｈ１８０５４Ｂ；Ｈ１Ｈ１８０５５Ｂ；Ｈ１Ｈ１８０５６Ｂ；Ｈ１Ｈ１８０５７Ｂ；Ｈ１Ｈ１８０５８Ｂ；Ｈ１Ｈ１８０５９Ｂ H1H18060B; H1H18061B; H1H18062B; H1H18063B; H1H18064B; H1H18065
Ｂ；Ｈ１Ｈ１８０６６Ｂ；Ｈ１Ｈ１８０６７Ｂ；Ｈ１Ｈ１８０６８Ｂ；Ｈ１Ｈ１８０６９Ｂ；Ｈ１Ｈ１８０７０Ｂ；Ｈ１Ｈ１８０７１Ｂ；Ｈ１Ｈ１８０７２Ｂ；Ｈ１Ｈ１８０７３Ｂ；Ｈ１Ｈ１８０７４Ｂ；Ｈ１Ｈ１８０７５Ｂ；Ｈ１Ｈ１８０７６Ｂ；Ｈ１Ｈ１８０７７Ｂ；Ｈ１Ｈ１８０７８Ｂ；Ｈ１Ｈ１８０７９Ｂ；Ｈ１Ｈ１８０８０Ｂ；Ｈ１Ｈ１８０８１Ｂ；Ｈ１Ｈ１８０８２Ｂ；Ｈ１Ｈ１８０８３Ｂ；Ｈ１Ｈ１８０８４Ｂ；Ｈ１Ｈ１８０８５Ｂ；Ｈ１Ｈ１８０８６Ｂ；Ｈ１Ｈ１８０８７Ｂ；Ｈ１Ｈ１８０８８Ｂ；Ｈ１Ｈ１８０８９Ｂ； Ｈ１Ｈ１８０９０Ｂ；Ｈ１Ｈ１８０９１Ｂ；Ｈ１Ｈ１８０９２Ｂ；Ｈ１Ｈ１８０９３Ｂ；Ｈ１Ｈ１８０９４Ｂ；Ｈ１Ｈ１８０９５Ｂ；Ｈ１Ｈ１８０９６Ｂ；Ｈ１Ｈ１８０９７Ｂ；Ｈ１Ｈ１８０９８Ｂ；Ｈ１Ｈ１８０９９Ｂ；Ｈ１Ｈ１８１００Ｂ；Ｈ１Ｈ１８１０１Ｂ；Ｈ１Ｈ１８１０２Ｂ；Ｈ１Ｈ１８１０３Ｂ；Ｈ１Ｈ１８１０４Ｂ；Ｈ１Ｈ１８１０５Ｂ；Ｈ１Ｈ１８１０７Ｂ；Ｈ１Ｈ１８１０８Ｂ；Ｈ１Ｈ１８１０９Ｂ；Ｈ１Ｈ１８１１０Ｂ；Ｈ１Ｈ１８１１１Ｂ；Ｈ１Ｈ１８１１２Ｂ；Ｈ１Ｈ１８１１３Ｂ；Ｈ１Ｈ１８１１４Ｂ；Ｈ１Ｈ１８１１５Ｂ； Ｈ１Ｈ１８１１６Ｂ；Ｈ１Ｈ１８１１７Ｂ；Ｈ１Ｈ１８１１８Ｂ；Ｈ１Ｈ１８１１９Ｂ；Ｈ１Ｈ１８１２０Ｂ；Ｈ１Ｈ１８１２１Ｂ；Ｈ１Ｈ１８１２２Ｂ；Ｈ１Ｈ１８１２３Ｂ；Ｈ１Ｈ１８１２４Ｂ；Ｈ１Ｈ１８１２５Ｂ；Ｈ１Ｈ１８１２６Ｂ；Ｈ１Ｈ１８１２７Ｂ；Ｈ１Ｈ１８１２８Ｂ；Ｈ１Ｈ１８１２９Ｂ；Ｈ１Ｈ１８１３０Ｂ；Ｈ１Ｈ１８１３１Ｂ；Ｈ１Ｈ１８１３２Ｂ；Ｈ１Ｈ１８１３３Ｂ；Ｈ１Ｈ１８１３４Ｂ；Ｈ１Ｈ１８１３５Ｂ；Ｈ１Ｈ１８１３６Ｂ；Ｈ１Ｈ１８１３７Ｂ；Ｈ１Ｈ１８１３８Ｂ；Ｈ１Ｈ１８１３９Ｂ；Ｈ１Ｈ１８１４０Ｂ； Ｈ１Ｈ１８１４１Ｂ；Ｈ１Ｈ１８１４２Ｂ；Ｈ１Ｈ１８１４３Ｂ；Ｈ１Ｈ１８１４４Ｂ；Ｈ１Ｈ１８１４５Ｂ；Ｈ１Ｈ１８１４６Ｂ；Ｈ１Ｈ１８１４７Ｂ；Ｈ１Ｈ１８１４８Ｂ；Ｈ１Ｈ１８１４９Ｂ；Ｈ１Ｈ１８１５０Ｂ；Ｈ１Ｈ１８１５１Ｂ；Ｈ１Ｈ１８１５２Ｂ；Ｈ１Ｈ１８１５３Ｂ；Ｈ１Ｈ１８１５４Ｂ；Ｈ１Ｈ１８１５５Ｂ；Ｈ１Ｈ１８１５６Ｂ；Ｈ１Ｈ１８１５７Ｂ；Ｈ１Ｈ１８１５８Ｂ；Ｈ１Ｈ１８１５９Ｂ；Ｈ１Ｈ１８１６０Ｂ；Ｈ１Ｈ１８１６１Ｂ；Ｈ１Ｈ１８１６２Ｂ；Ｈ１Ｈ１８１６３Ｂ；Ｈ１Ｈ１８１６４Ｂ；Ｈ１Ｈ１８１６５Ｂ； H1H18166 Ｂ；Ｈ１Ｈ１８１６７Ｂ；Ｈ１Ｈ１８１６８Ｂ；Ｈ１Ｈ１８１６９Ｂ；Ｈ１Ｈ１８１７０Ｂ；Ｈ１Ｈ１８１７１Ｂ；Ｈ１Ｈ１８１７２Ｂ；Ｈ１Ｈ１８１７３Ｂ；Ｈ１Ｈ１８１７４Ｂ；Ｈ１Ｈ１８１７５Ｂ；Ｈ１Ｈ１８１７６Ｂ；Ｈ１Ｈ１８１７７Ｂ；Ｈ１Ｈ１８１７８Ｂ；Ｈ１Ｈ１８１７９Ｂ；Ｈ１Ｈ１８１８０Ｂ；Ｈ１Ｈ１８１８１Ｂ；Ｈ１Ｈ１８１８２Ｂ；Ｈ１Ｈ１８１８３Ｂ；Ｈ１Ｈ１８１８４Ｂ；Ｈ１Ｈ１８１８５Ｂ；Ｈ１Ｈ１８１８６Ｂ；Ｈ１Ｈ１８１８７Ｂ；Ｈ１Ｈ１８１８８Ｂ；Ｈ１Ｈ１８１８９Ｂ；Ｈ１Ｈ１８１９０Ｂ； Ｈ１Ｈ１８１９１Ｂ；Ｈ１Ｈ１８１９２Ｂ；Ｈ１Ｈ１８１９３Ｂ；Ｈ１Ｈ１８１９４Ｂ；Ｈ１Ｈ１８１９５Ｂ；Ｈ１Ｈ１８１９６Ｂ；Ｈ１Ｈ１８１９７Ｂ；Ｈ１Ｈ１８１９８Ｂ；Ｈ１Ｈ１８１９９Ｂ；Ｈ１Ｈ１８２００Ｂ；Ｈ１Ｈ１８２０１Ｂ；Ｈ１Ｈ１８２０２Ｂ；Ｈ１Ｈ１８２０３Ｂ；Ｈ１Ｈ１８２０４Ｂ；Ｈ１Ｈ１８２０５Ｂ；Ｈ１Ｈ１８２０６Ｂ；Ｈ１Ｈ１８２０７Ｂ；Ｈ１Ｈ１８２０８Ｂ；Ｈ１Ｈ１８２０９Ｂ；Ｈ１Ｈ１８２１０Ｂ；Ｈ１Ｈ１８２１１Ｂ；Ｈ１Ｈ１８２１２Ｂ；Ｈ１Ｈ１８２１３Ｂ；Ｈ１Ｈ１８２１４Ｂ；Ｈ１Ｈ１８２１６Ｂ； Ｈ１Ｈ１８２１７Ｂ；Ｈ１Ｈ１８２１８Ｂ；Ｈ１Ｈ１８２１９Ｂ；Ｈ１Ｈ１８２２０Ｂ；Ｈ１Ｈ１８２２１Ｂ；Ｈ１Ｈ１８２２２Ｂ；Ｈ１Ｈ１８２２３Ｂ；Ｈ１Ｈ１８２２４Ｂ；Ｈ１Ｈ１８２２５Ｂ；Ｈ１Ｈ１８２２６Ｂ；Ｈ１Ｈ１８２２７Ｂ；Ｈ１Ｈ１８２２８Ｂ；Ｈ１Ｈ１８２２９Ｂ；Ｈ１Ｈ１８２３０Ｂ；Ｈ１Ｈ１８２３１Ｂ；Ｈ１Ｈ１８２３２Ｂ；Ｈ１Ｈ１８２３３Ｂ；Ｈ１Ｈ１８２３４Ｂ；Ｈ１Ｈ１８２３５Ｂ；Ｈ１Ｈ１８２３６Ｂ；Ｈ１Ｈ１８２３７Ｂ；Ｈ１Ｈ１８２３８Ｂ；Ｈ１Ｈ１８２３９Ｂ；Ｈ１Ｈ１８２４０Ｂ；Ｈ１Ｈ１８２４１Ｂ； Ｈ１Ｈ１８２４２Ｂ；Ｈ１Ｈ１８２４３Ｂ；Ｈ１Ｈ１８２４４Ｂ；Ｈ１Ｈ１８２４５Ｂ；Ｈ１Ｈ１８２４６Ｂ；Ｈ１Ｈ１８２４７Ｂ；Ｈ１Ｈ１８２４８Ｂ；Ｈ１Ｈ１８２４９Ｂ；Ｈ１Ｈ１８２５０Ｂ；Ｈ１Ｈ１８２５１Ｂ；Ｈ１Ｈ１８２５２Ｂ；Ｈ１Ｈ１８２５３Ｂ；Ｈ１Ｈ１８２５４Ｂ；Ｈ１Ｈ１８２５５Ｂ；Ｈ１Ｈ１８２５６Ｂ；Ｈ１Ｈ１８２５７Ｂ；Ｈ１Ｈ１８２５８Ｂ；Ｈ１Ｈ１８２５９Ｂ；Ｈ１Ｈ１８２６１Ｂ；Ｈ１Ｈ１８２６２Ｂ；Ｈ１Ｈ１８２６３Ｂ；Ｈ１Ｈ１８２６４Ｂ；Ｈ１Ｈ１８２６５Ｂ；Ｈ１Ｈ１８２６６Ｂ；Ｈ１Ｈ１８２６７Ｂ； H1H18268
Ｂ；Ｈ１Ｈ１８２６９Ｂ；Ｈ１Ｈ１８２７０Ｂ；Ｈ１Ｈ１８２７１Ｂ；Ｈ１Ｈ１８２７２Ｂ；Ｈ１Ｈ１８２７４Ｂ；Ｈ１Ｈ１８２７５Ｂ；Ｈ１Ｈ１８２７６Ｂ；Ｈ１Ｈ１８２７７Ｂ；Ｈ１Ｈ１８２７８Ｂ；Ｈ１Ｈ１８２７９Ｂ；Ｈ１Ｈ１８２８０Ｂ；Ｈ１Ｈ１８２８１Ｂ；Ｈ１Ｈ１８２８２Ｂ；Ｈ１Ｈ１８２８３Ｂ；Ｈ１Ｈ１８２８４Ｂ；Ｈ１Ｈ１８２８５Ｂ；Ｈ１Ｈ１８２８６Ｂ；Ｈ１Ｈ１８２８７Ｂ；Ｈ１Ｈ１８２８８Ｂ；Ｈ１Ｈ１８２８９Ｂ；Ｈ１Ｈ１８２９０Ｂ；Ｈ１Ｈ１８２９１Ｂ；Ｈ１Ｈ１８２９２Ｂ；Ｈ１Ｈ１８２９３Ｂ； Ｈ１Ｈ１８２９４Ｂ；Ｈ１Ｈ１８２９５Ｂ；Ｈ１Ｈ１８２９７Ｂ；Ｈ１Ｈ１８２９８Ｂ；Ｈ１Ｈ１８２９９Ｂ；Ｈ１Ｈ１８３００Ｂ；Ｈ１Ｈ１８３０１Ｂ；Ｈ１Ｈ１８３０２Ｂ；Ｈ１Ｈ１８３０３Ｂ；Ｈ１Ｈ１８３０４Ｂ；Ｈ１Ｈ１８３０５Ｂ；Ｈ１Ｈ１８３０６Ｂ；Ｈ１Ｈ１８３０７Ｂ；Ｈ１Ｈ１８３０８Ｂ；Ｈ１Ｈ１８３０９Ｂ；Ｈ１Ｈ１８３１０Ｂ；Ｈ１Ｈ１８３１１Ｂ；Ｈ１Ｈ１８３１２Ｂ；Ｈ１Ｈ１８３１３Ｂ；Ｈ１Ｈ１８３１４Ｂ；Ｈ１Ｈ１８３１５Ｂ；Ｈ１Ｈ１８３１６Ｂ；Ｈ１Ｈ１８３１７Ｂ；Ｈ１Ｈ１８３１８Ｂ；Ｈ１Ｈ１８３１９Ｂ； H1H18320B; H1H18321B; H1H18322B; H1H18323B; H1H18324B; H1H18325B; H1H18326B; H1H18327B; H1H18328B; H1H18329B; H1H1832B; The pharmaceutical composition according to claim 24 or 25, wherein a further therapeutic agent is administered to the subject. 請求項１～９のいずれか１項に記載の抗原結合タンパク質または請求項１４もしくは１５に記載のポリペプチドを含む医薬組成物であって、該医薬組成物は注入のために製剤化されていることを特徴とする、前記医薬組成物。 A pharmaceutical composition comprising the antigen-binding protein according to any one of claims 1 to 9 or the polypeptide according to claim 14 or 15, wherein the pharmaceutical composition is formulated for injection. The pharmaceutical composition. 医薬組成物は、皮下、静脈内または筋肉内注入のために製剤化されていることを特徴とする、請求項２９に記載の医薬組成物。 29. The pharmaceutical composition of claim 29, wherein the pharmaceutical composition is formulated for subcutaneous, intravenous or intramuscular injection.
JP2020540397A 2018-01-26 2019-01-24 Anti-TMPRSS2 antibody and antigen binding fragment Pending JP2021511058A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023177262A JP2024009962A (en) 2018-01-26 2023-10-13 Anti-TMPRSS2 antibodies and antigen-binding fragments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622292P 2018-01-26 2018-01-26
US62/622,292 2018-01-26
PCT/US2019/014978 WO2019147831A1 (en) 2018-01-26 2019-01-24 Anti-tmprss2 antibodies and antigen-binding fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023177262A Division JP2024009962A (en) 2018-01-26 2023-10-13 Anti-TMPRSS2 antibodies and antigen-binding fragments

Publications (2)

Publication Number Publication Date
JP2021511058A JP2021511058A (en) 2021-05-06
JPWO2019147831A5 true JPWO2019147831A5 (en) 2022-01-21

Family

ID=66102175

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540397A Pending JP2021511058A (en) 2018-01-26 2019-01-24 Anti-TMPRSS2 antibody and antigen binding fragment
JP2023177262A Pending JP2024009962A (en) 2018-01-26 2023-10-13 Anti-TMPRSS2 antibodies and antigen-binding fragments

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023177262A Pending JP2024009962A (en) 2018-01-26 2023-10-13 Anti-TMPRSS2 antibodies and antigen-binding fragments

Country Status (25)

Country Link
US (3) US10941213B2 (en)
EP (1) EP3638698B1 (en)
JP (2) JP2021511058A (en)
KR (1) KR20200115576A (en)
CN (1) CN111936517A (en)
AU (1) AU2019211406A1 (en)
BR (1) BR112020015112A2 (en)
CA (1) CA3089377A1 (en)
CY (1) CY1124182T1 (en)
DK (1) DK3638698T3 (en)
ES (1) ES2864529T3 (en)
HR (1) HRP20210876T1 (en)
HU (1) HUE054403T2 (en)
IL (1) IL276164A (en)
LT (1) LT3638698T (en)
MA (1) MA46731B1 (en)
MD (1) MD3638698T2 (en)
MX (1) MX2020007888A (en)
PL (1) PL3638698T3 (en)
PT (1) PT3638698T (en)
RS (1) RS61825B1 (en)
SG (1) SG11202006898TA (en)
SI (1) SI3638698T1 (en)
WO (1) WO2019147831A1 (en)
ZA (1) ZA202004494B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI701258B (en) * 2014-12-19 2020-08-11 美商再生元醫藥公司 Human antibodies to influenza hemagglutinin
JP2022548783A (en) * 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション Single domain antibody variant nucleic acid library
AU2021219671A1 (en) * 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
KR20210134300A (en) 2020-04-02 2021-11-09 리제너론 파아마슈티컬스, 인크. Anti-SARS-COV-2 Spike Glycoprotein Antibodies and Antigen-Binding Fragments
WO2021211402A2 (en) * 2020-04-13 2021-10-21 Maddon Advisors Llc Ace2-targeted compositions and methods for treating covid-19
CN116075725A (en) 2020-04-17 2023-05-05 瑞泽恩制药公司 Assay for coronavirus neutralizing antibodies
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
MX2022014598A (en) 2020-05-26 2023-03-31 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments.
US20210379091A1 (en) * 2020-06-08 2021-12-09 Brigham Young University Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
WO2021255217A1 (en) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
CN111986818A (en) * 2020-08-21 2020-11-24 南通大学 New crown COVID-19 treatment drug screening system based on TMPRSS2
CN112795583A (en) * 2020-11-16 2021-05-14 上海大学 Preparation method of recombinant sialic acid exonuclease, expression gene, recombinant expression vector and construction method
WO2022115503A1 (en) 2020-11-25 2022-06-02 Dupont Nutrition Biosciences Aps Treatment and prevention of coronavirus infection
CN112538494A (en) * 2020-12-08 2021-03-23 武汉华美生物工程有限公司 TMPRSS2 mutant protein, expression vector, expression engineering bacterium and preparation method thereof
WO2022133182A1 (en) * 2020-12-18 2022-06-23 Chan Zuckerberg Biohub, Inc. Method of treating coronavirus infection
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
AU2022311906A1 (en) 2021-07-14 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023199943A1 (en) * 2022-04-12 2023-10-19 国立研究開発法人理化学研究所 Antibody used to treat coronavirus infection
WO2023220712A1 (en) * 2022-05-13 2023-11-16 The Trustees Of Columbia University In The City Of New York Host proteases essential for parainfluenza spread in the human lung: potential targets for antiviral interventions
CN116003611B (en) * 2022-08-17 2024-02-27 中南大学湘雅医院 anti-TMPRSS 2 antibodies and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
AU2002218786A1 (en) * 2000-07-12 2002-01-21 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8354508B2 (en) 2006-07-21 2013-01-15 Diadexus, Inc. PRO115 antibody compositions and methods of use
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
BRPI0911984A2 (en) 2008-05-16 2016-09-20 Ablynx Nv amino acid sequences directed against cxcr4 and other gpcrs compounds comprising the same
LT3453723T (en) * 2012-01-31 2021-09-10 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
SG11201405163RA (en) * 2012-04-16 2014-09-26 Regeneron Pharma Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
TWI701258B (en) * 2014-12-19 2020-08-11 美商再生元醫藥公司 Human antibodies to influenza hemagglutinin
CN106589127A (en) * 2015-10-16 2017-04-26 钜川生物医药 PCSK9 antibody, preparation method and application thereof
DK3422845T3 (en) 2016-02-29 2021-08-30 Regeneron Pharma GNAGER WITH A HUMANIZED TMPRSS GENE
US11466080B2 (en) * 2017-03-22 2022-10-11 Children's Medical Center Corporation Methods of treating cancer using anti-LRP1 polyclonal antibodies

Similar Documents

Publication Publication Date Title
JPWO2019147831A5 (en)
HRP20210876T1 (en) Anti-tmprss2 antibodies and antigen-binding fragments
RU2019141289A (en) ANTI-SIRPα ANTIBODIES
JP2018527919A5 (en)
JP2019526273A5 (en)
JP2020532965A5 (en)
JP2020501531A5 (en)
JP2020520370A5 (en)
JP2020528768A5 (en)
JP2019533719A5 (en)
JP2017529838A5 (en)
JP2018510636A5 (en)
JP2016531915A5 (en)
RU2016129113A (en) ANTIBODIES TO PD-1 DOGS
JP2017506067A5 (en)
RU2014113304A (en) ANTI-CD40-ANTIBODIES, APPLICATION AND METHODS
JPWO2019129221A5 (en)
RU2013125459A (en) ANTIBODIES AGAINST c-Met RECEPTOR PROTEIN
RU2009136913A (en) BISPECIFIC BINDING AGENTS WITH INTER-SPECIFIC SPECIFICITY
JP2010509931A5 (en)
US20220340673A1 (en) Antibody targeting bcma, bispecific antibody, and use thereof
RU2013106217A (en) HYBRID PROTEIN FROM ANTIBODIES AGAINST MHC AND ANTIVIRAL CYTOKINE
JP2024016024A5 (en)
JP2020533965A5 (en)
JPWO2020198009A5 (en)